<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:01:05Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4884786" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:4884786</identifier><datestamp>2016-08-05</datestamp><setSpec>emboj</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">EMBO J</journal-id>
      <journal-id journal-id-type="iso-abbrev">EMBO J</journal-id>
      <journal-id journal-id-type="doi">10.1002/(ISSN)1460-2075</journal-id>
      <journal-id journal-id-type="publisher-id">EMBJ</journal-id>
      <journal-id journal-id-type="hwp">embojnl</journal-id>
      <journal-title-group>
        <journal-title>The EMBO Journal</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0261-4189</issn>
      <issn pub-type="epub">1460-2075</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4884786</article-id>
      <article-id pub-id-type="pmcid">PMC4884786</article-id>
      <article-id pub-id-type="pmc-uid">4884786</article-id>
      <article-id pub-id-type="pmid">27234298</article-id>
      <article-id pub-id-type="pmid">27234298</article-id>
      <article-id pub-id-type="doi">10.15252/embj.201593374</article-id>
      <article-id pub-id-type="publisher-id">EMBJ201593374</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Article</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>
<styled-content style="fixed-case">SCF</styled-content> (Fbxl17) ubiquitylation of Sufu regulates Hedgehog signaling and medulloblastoma development</article-title>
        <alt-title alt-title-type="left-running-head">Madalina Raducu <italic>etÂ al</italic></alt-title>
      </title-group>
      <contrib-group>
        <contrib id="embj201593374-cr-0001" contrib-type="author">
          <name>
            <surname>Raducu</surname>
            <given-names>Madalina</given-names>
          </name>
          <xref ref-type="aff" rid="embj201593374-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="embj201593374-cr-0002" contrib-type="author">
          <name>
            <surname>Fung</surname>
            <given-names>Ella</given-names>
          </name>
          <xref ref-type="aff" rid="embj201593374-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="embj201593374-cr-0003" contrib-type="author">
          <name>
            <surname>Serres</surname>
            <given-names>SÃ©bastien</given-names>
          </name>
          <xref ref-type="aff" rid="embj201593374-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="embj201593374-cr-0004" contrib-type="author">
          <name>
            <surname>Infante</surname>
            <given-names>Paola</given-names>
          </name>
          <xref ref-type="aff" rid="embj201593374-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="embj201593374-cr-0005" contrib-type="author">
          <name>
            <surname>Barberis</surname>
            <given-names>Alessandro</given-names>
          </name>
          <xref ref-type="aff" rid="embj201593374-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="embj201593374-cr-0006" contrib-type="author">
          <name>
            <surname>Fischer</surname>
            <given-names>Roman</given-names>
          </name>
          <xref ref-type="aff" rid="embj201593374-aff-0003">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="embj201593374-cr-0007" contrib-type="author">
          <name>
            <surname>Bristow</surname>
            <given-names>Claire</given-names>
          </name>
          <xref ref-type="aff" rid="embj201593374-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="embj201593374-cr-0008" contrib-type="author">
          <name>
            <surname>ThÃ©zÃ©nas</surname>
            <given-names>MarieâLaÃ«titia</given-names>
          </name>
          <xref ref-type="aff" rid="embj201593374-aff-0003">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="embj201593374-cr-0009" contrib-type="author">
          <name>
            <surname>Finta</surname>
            <given-names>Csaba</given-names>
          </name>
          <xref ref-type="aff" rid="embj201593374-aff-0004">
<sup>4</sup>
</xref>
        </contrib>
        <contrib id="embj201593374-cr-0010" contrib-type="author">
          <name>
            <surname>Christianson</surname>
            <given-names>John C</given-names>
          </name>
          <xref ref-type="aff" rid="embj201593374-aff-0005">
<sup>5</sup>
</xref>
        </contrib>
        <contrib id="embj201593374-cr-0011" contrib-type="author">
          <name>
            <surname>Buffa</surname>
            <given-names>Francesca M</given-names>
          </name>
          <xref ref-type="aff" rid="embj201593374-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="embj201593374-cr-0012" contrib-type="author">
          <name>
            <surname>Kessler</surname>
            <given-names>Benedikt M</given-names>
          </name>
          <xref ref-type="aff" rid="embj201593374-aff-0003">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="embj201593374-cr-0013" contrib-type="author">
          <name>
            <surname>Sibson</surname>
            <given-names>Nicola R</given-names>
          </name>
          <xref ref-type="aff" rid="embj201593374-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="embj201593374-cr-0014" contrib-type="author">
          <name>
            <surname>Di Marcotullio</surname>
            <given-names>Lucia</given-names>
          </name>
          <xref ref-type="aff" rid="embj201593374-aff-0006">
<sup>6</sup>
</xref>
          <xref ref-type="aff" rid="embj201593374-aff-0007">
<sup>7</sup>
</xref>
        </contrib>
        <contrib id="embj201593374-cr-0015" contrib-type="author">
          <name>
            <surname>ToftgÃ¥rd</surname>
            <given-names>Rune</given-names>
          </name>
          <xref ref-type="aff" rid="embj201593374-aff-0004">
<sup>4</sup>
</xref>
        </contrib>
        <contrib id="embj201593374-cr-0016" contrib-type="author" corresp="yes">
          <name>
            <surname>D'Angiolella</surname>
            <given-names>Vincenzo</given-names>
          </name>
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8365-9094</contrib-id>
          <xref ref-type="aff" rid="embj201593374-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="embj201593374-aff-0001">
        <label>
          <sup>1</sup>
        </label>
        <named-content content-type="organisation-division">Cancer Research UK and Medical Research Council Institute for Radiation Oncology</named-content>
        <named-content content-type="organisation-division">Department of Oncology</named-content>
        <institution>University of Oxford</institution>
        <named-content content-type="city">Oxford</named-content>
        <country country="GB">UK</country>
      </aff>
      <aff id="embj201593374-aff-0002">
        <label>
          <sup>2</sup>
        </label>
        <named-content content-type="organisation-division">Center for Life NanoScience@Sapienza</named-content>
        <institution>Istituto Italiano di Tecnologia</institution>
        <named-content content-type="city">Rome</named-content>
        <country country="IT">Italy</country>
      </aff>
      <aff id="embj201593374-aff-0003">
        <label>
          <sup>3</sup>
        </label>
        <named-content content-type="organisation-division">Target Discovery Institute</named-content>
        <named-content content-type="organisation-division">Nuffield Department of Medicine</named-content>
        <institution>University of Oxford</institution>
        <named-content content-type="city">Oxford</named-content>
        <country country="GB">UK</country>
      </aff>
      <aff id="embj201593374-aff-0004">
        <label>
          <sup>4</sup>
        </label>
        <named-content content-type="organisation-division">Department of Biosciences and Nutrition</named-content>
        <named-content content-type="organisation-division">Center for Innovative Medicine</named-content>
        <institution>Karolinska Institutet</institution>
        <named-content content-type="city">Huddinge</named-content>
        <country country="SE">Sweden</country>
      </aff>
      <aff id="embj201593374-aff-0005">
        <label>
          <sup>5</sup>
        </label>
        <named-content content-type="organisation-division">Ludwig Institute for Cancer Research</named-content>
        <institution>University of Oxford</institution>
        <named-content content-type="city">Oxford</named-content>
        <country country="GB">UK</country>
      </aff>
      <aff id="embj201593374-aff-0006">
        <label>
          <sup>6</sup>
        </label>
        <named-content content-type="organisation-division">Department of Molecular Medicine</named-content>
        <institution>University âLa Sapienzaâ</institution>
        <named-content content-type="city">Rome</named-content>
        <country country="IT">Italy</country>
      </aff>
      <aff id="embj201593374-aff-0007">
        <label>
          <sup>7</sup>
        </label>
        <institution>Pasteur Institute/Cenci Bolognetti Foundation</institution>
        <institution>Sapienza University</institution>
        <named-content content-type="city">Rome</named-content>
        <country country="IT">Italy</country>
      </aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label>Corresponding author. Tel: +44 01865617400; Eâmail: <email>vincenzo.dangiolella@oncology.ox.ac.uk</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>27</day>
        <month>5</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <day>01</day>
        <month>7</month>
        <year>2016</year>
      </pub-date>
      <volume>35</volume>
      <issue>13</issue>
      <issue-id pub-id-type="doi">10.1002/embj.v35.13</issue-id>
      <fpage>1400</fpage>
      <lpage>1416</lpage>
      <history>
        <date date-type="received">
          <day>28</day>
          <month>10</month>
          <year>2015</year>
        </date>
        <date date-type="rev-recd">
          <day>28</day>
          <month>4</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>4</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2016 EMBO <copyright-statement>-->
        <copyright-statement content-type="article-copyright">Â© 2016 The Authors. Published under the terms of the CC BY 4.0 license</copyright-statement>
        <license license-type="creativeCommonsBy">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:EMBJ-35-1400.pdf"/>
      <abstract id="embj201593374-abs-0001">
        <title>Abstract</title>
        <p>Skp1âCul1âFâbox protein (SCF) ubiquitin ligases direct cell survival decisions by controlling protein ubiquitylation and degradation. Sufu (Suppressor of fused) is a central regulator of Hh (Hedgehog) signaling and acts as a tumor suppressor by maintaining the Gli (Gliomaâassociated oncogene homolog) transcription factors inactive. Although Sufu has a pivotal role in Hh signaling, the players involved in controlling Sufu levels and their role in tumor growth are unknown. Here, we show that Fbxl17 (Fâbox and leucineârich repeat protein 17) targets Sufu for proteolysis in the nucleus. The ubiquitylation of Sufu, mediated by Fbxl17, allows the release of Gli1 from Sufu for proper Hh signal transduction. Depletion of Fbxl17 leads to defective Hh signaling associated with an impaired cancer cell proliferation and medulloblastoma tumor growth. Furthermore, we identify a mutation in Sufu, occurring in medulloblastoma of patients with Gorlin syndrome, which increases Sufu turnover through Fbxl17âmediated polyubiquitylation and leads to a sustained Hh signaling activation. In summary, our findings reveal Fbxl17 as a novel regulator of Hh pathway and highlight theÂ perturbation of the Fbxl17âSufu axis in the pathogenesis of medulloblastoma.</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated">
        <kwd id="embj201593374-kwd-0001">Fâbox protein</kwd>
        <kwd id="embj201593374-kwd-0002">Fbxl17</kwd>
        <kwd id="embj201593374-kwd-0003">Hedgehog signaling</kwd>
        <kwd id="embj201593374-kwd-0004">medulloblastoma</kwd>
        <kwd id="embj201593374-kwd-0005">Sufu</kwd>
      </kwd-group>
      <kwd-group kwd-group-type="subject-categories">
        <title>Subject Categories</title>
        <kwd>Cancer</kwd>
        <kwd>Post-translational Modifications, Proteolysis &amp; Proteomics</kwd>
        <kwd>Signal Transduction</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>Medical Research Council (MRC)</funding-source>
          <award-id>MC_PC_12007</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Cancer Research UK</funding-source>
          <award-id>C5255/A12678</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Swedish Research Council</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Swedish Cancer Society</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Center for Innovative Medicine at Karolinska Institutet</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>John Fell Fund</funding-source>
          <award-id>133/075</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Wellcome Trust</funding-source>
          <award-id>097813/Z/11/Z</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Associazione Italiana per la Ricerca sul Cancro</funding-source>
          <award-id>IG#14723</award-id>
        </award-group>
      </funding-group>
      <counts>
        <page-count count="17"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>component-id</meta-name>
          <meta-value>embj201593374</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>1 July 2016</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.1 mode:remove_FC converted:04.07.2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <p content-type="self-citation">
<mixed-citation publication-type="journal" id="embj201593374-cit-5001">
<source>The EMBO Journal</source> (<year>2016</year>) <volume>35</volume>: <fpage>1400</fpage>â<lpage>1416</lpage>
<pub-id pub-id-type="pmid">27234298</pub-id></mixed-citation>
</p>
    </notes>
  </front>
  <body>
    <sec id="embj201593374-sec-0001">
      <title>Introduction</title>
      <p>Signals of the Hh (Hedgehog) pathway are essential in directing cell proliferation and patterning during embryogenesis (Hooper &amp; Scott, <xref rid="embj201593374-bib-0020" ref-type="ref">2005</xref>; Ingham <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0024" ref-type="ref">2011</xref>). The pathway lays at the crossâroad of cell survival and differentiation decisions, and unscheduled Hh signaling can lead to hyperproliferation and the development of malignancies. Indeed, alterations of pathway components have been described in multiple cancer types (Teglund &amp; Toftgard, <xref rid="embj201593374-bib-0059" ref-type="ref">2010</xref>).</p>
      <p>Hh signaling is initiated at the cell membrane by the inactivation of the 12âpass transmembrane receptor Ptch (Patched) upon binding of the Hh ligands (Ingham <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0024" ref-type="ref">2011</xref>). Ptch inactivation frees the cognate receptor Smo (Smoothened) leading to the downstream activation of a transcriptional program mediated by Gli1, Gli2, and Gli3 (Gliomaâassociated oncogene homolog 1, 2, and 3) transcription factors (Hui &amp; Angers, <xref rid="embj201593374-bib-0022" ref-type="ref">2011</xref>).</p>
      <p>Sufu (Suppressor of fused) acts as a central negative regulator of Hh signaling by sequestering the Gli transcription factors in an inactive complex (Kogerman <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0029" ref-type="ref">1999</xref>; Dunaeva <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0014" ref-type="ref">2003</xref>; Merchant <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0100" ref-type="ref">2004</xref>; Humke <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0023" ref-type="ref">2010</xref>). Sufu deletion in mice leads to the continuous activation of Hh signal and embryonic lethality at day 9.5 (Cooper <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0008" ref-type="ref">2005</xref>; Svard <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0055" ref-type="ref">2006</xref>), underscoring the essential role of Sufu for proper development. Importantly, heterozygous loss of Sufu, in conjunction with the loss of p53, leads to the development of medulloblastoma and rhabdomyosarcoma (Lee <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0033" ref-type="ref">2007</xref>). Germline Sufu mutations have been identified in medulloblastoma (Taylor <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0058" ref-type="ref">2002</xref>; Kool <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0030" ref-type="ref">2014</xref>) and associated with the development of medulloblastoma in Gorlin syndrome (Pastorino <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0041" ref-type="ref">2009</xref>; Kijima <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0028" ref-type="ref">2012</xref>; Smith <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0053" ref-type="ref">2014</xref>). Furthermore, somatic Sufu mutations have been identified in multiple otherÂ malignancies, including prostate cancer (Sheng <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0049" ref-type="ref">2004</xref>). Sufu has a pivotal role in Hh signaling and is a relevant tumor suppressor, but the players involved in controlling Sufu levels are unknown and the relevance for cancer proliferation remains unrecognized.</p>
      <p>Using an unbiased proteomic approach, we have identified Sufu as an interacting partner of the E3 ubiquitin ligase Fbxl17 (Fâbox and leucineârich repeat protein 17). Fbxl17 belongs to a family of E3 ubiquitin ligases containing a leucineârich repeat and an Fâbox motif, which mediate binding to Skp1 (Sâphase kinaseâassociated protein 1) (Skaar <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0050" ref-type="ref">2009</xref>). Skp1 in turn recruits Cul1 (Cullin 1) and Rbx1 (RINGâbox protein 1) for the formation of an SCF (Skp1âCul1âFâbox protein) complex. The multiâsubunit SCF directs the polyubiquitylation of target substrates by recruiting an E2 enzyme with an activated ubiquitin molecule ready to be transferred on accepting lysines of target substrates. Substrate specificity is dictated by the presence of variable proteinâprotein interaction domains within diverse Fâbox proteins (Skaar <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0051" ref-type="ref">2013</xref>). According to the type of proteinâprotein interaction domain, three subfamilies of Fâbox proteins have been identified in the human genome: Fbxws (containing WD40 repeats), Fbxls (containing leucineârich repeats, LRR), and Fbxos (containing other interacting motifs) (Jin <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0025" ref-type="ref">2004</xref>).</p>
      <p>Fâbox proteins can function as tumor suppressor or oncogenes and have been implicated in the control of cell proliferation and cancer development (D'Angiolella <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0010" ref-type="ref">2012</xref>; Bassermann <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0003" ref-type="ref">2014</xref>). Novel compounds targeting Fâbox proteins have been developed, and therefore, Fâbox proteins represent candidate pharmacological targets to treat cancer (Skaar <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0052" ref-type="ref">2014</xref>). However, few Fâbox proteins have been matched to substrates and biological roles.</p>
      <p>Here, we show that Fbxl17 forms a functional SCF complex and targets the tumor suppressor Sufu for proteolysis in the nuclear compartment upon Hh pathway activation. The ubiquitylation of Sufu, mediated by Fbxl17, allows the release of Gli1 for full activation of the Hh signaling. Extending our basic biological finding to the significance of the Fbxl17âSufu axis <italic>inÂ vivo</italic>, we have identified Fbxl17 as a crucial regulator of cell proliferation in medulloblastoma.</p>
      <p>Finally, we show that in human disease, a somatic mutation in Sufu, occurring in medulloblastoma of patients with Gorlin syndrome, increases Sufu turnover through Fbxl17 polyubiquitylation, leading to a sustained Hh signaling and cell proliferation. Our study highlights the alteration in Fbxl17âSufu axis as an etiological mechanism of medulloblastoma.</p>
    </sec>
    <sec id="embj201593374-sec-0002">
      <title>Results</title>
      <sec id="embj201593374-sec-0003">
        <title>Fbxl17 interacts with Sufu and regulates Sufu levels</title>
        <p>To identify the putative functions and substrates of Fbxl17, we isolated Fbxl17 and interacting proteins from HEK293T cells. Liquid chromatographyâtandem mass spectrometry (LCâMS/MS) of the immunoprecipitated material identified peptides corresponding to components of the SCF complex (Skp1 and Cul1), peptides corresponding to BACH1 (BTB and CNC homology 1 protein, a known substrate of Fbxl17) (Tan <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0057" ref-type="ref">2013</xref>) as well as putative novel substrates such as Sufu and ZBTB33 (Zinc Finger and BTB domain containing 33) (TableÂ <xref rid="embj201593374-tbl-0001" ref-type="table-wrap">1</xref>).</p>
        <table-wrap id="embj201593374-tbl-0001" xml:lang="en" orientation="portrait" position="float">
          <label>Table 1</label>
          <caption>
            <p>Proteins associated with Fbxl17 identified by mass spectrometry</p>
          </caption>
          <table frame="hsides" rules="groups">
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <thead valign="top">
              <tr style="border-bottom:solid 1px #000000">
                <th align="left" valign="top" rowspan="1" colspan="1">Accession</th>
                <th align="char" valign="top" rowspan="1" colspan="1">Score</th>
                <th align="char" valign="top" rowspan="1" colspan="1">Mass</th>
                <th align="char" valign="top" rowspan="1" colspan="1">No. matches</th>
                <th align="char" valign="top" rowspan="1" colspan="1">No. sig. matches</th>
                <th align="char" valign="top" rowspan="1" colspan="1">No. seq</th>
                <th align="char" valign="top" rowspan="1" colspan="1">No. sig. seq</th>
                <th align="char" valign="top" rowspan="1" colspan="1">emPAI</th>
                <th align="left" valign="top" rowspan="1" colspan="1">Description</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">Q9UF56</td>
                <td align="char" char="." rowspan="1" colspan="1">33,624</td>
                <td align="char" char="." rowspan="1" colspan="1">77,984</td>
                <td align="char" char="." rowspan="1" colspan="1">1,316</td>
                <td align="char" char="." rowspan="1" colspan="1">1,081</td>
                <td align="char" char="." rowspan="1" colspan="1">76</td>
                <td align="char" char="." rowspan="1" colspan="1">74</td>
                <td align="char" char="." rowspan="1" colspan="1">178.17</td>
                <td align="left" rowspan="1" colspan="1">Fbxl17</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">P63208</td>
                <td align="char" char="." rowspan="1" colspan="1">8,032</td>
                <td align="char" char="." rowspan="1" colspan="1">18,817</td>
                <td align="char" char="." rowspan="1" colspan="1">297</td>
                <td align="char" char="." rowspan="1" colspan="1">243</td>
                <td align="char" char="." rowspan="1" colspan="1">17</td>
                <td align="char" char="." rowspan="1" colspan="1">15</td>
                <td align="char" char="." rowspan="1" colspan="1">59.82</td>
                <td align="left" rowspan="1" colspan="1">Skp1</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Q13616</td>
                <td align="char" char="." rowspan="1" colspan="1">248</td>
                <td align="char" char="." rowspan="1" colspan="1">90,306</td>
                <td align="char" char="." rowspan="1" colspan="1">14</td>
                <td align="char" char="." rowspan="1" colspan="1">12</td>
                <td align="char" char="." rowspan="1" colspan="1">9</td>
                <td align="char" char="." rowspan="1" colspan="1">7</td>
                <td align="char" char="." rowspan="1" colspan="1">0.28</td>
                <td align="left" rowspan="1" colspan="1">Cul1</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Q9UMX1</td>
                <td align="char" char="." rowspan="1" colspan="1">112</td>
                <td align="char" char="." rowspan="1" colspan="1">54,255</td>
                <td align="char" char="." rowspan="1" colspan="1">9</td>
                <td align="char" char="." rowspan="1" colspan="1">5</td>
                <td align="char" char="." rowspan="1" colspan="1">3</td>
                <td align="char" char="." rowspan="1" colspan="1">3</td>
                <td align="char" char="." rowspan="1" colspan="1">0.27</td>
                <td align="left" rowspan="1" colspan="1">Sufu</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Q96DT7</td>
                <td align="char" char="." rowspan="1" colspan="1">102</td>
                <td align="char" char="." rowspan="1" colspan="1">95,975</td>
                <td align="char" char="." rowspan="1" colspan="1">6</td>
                <td align="char" char="." rowspan="1" colspan="1">3</td>
                <td align="char" char="." rowspan="1" colspan="1">4</td>
                <td align="char" char="." rowspan="1" colspan="1">3</td>
                <td align="char" char="." rowspan="1" colspan="1">0.11</td>
                <td align="left" rowspan="1" colspan="1">ZBTB10</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Q9BY89</td>
                <td align="char" char="." rowspan="1" colspan="1">79</td>
                <td align="char" char="." rowspan="1" colspan="1">197,617</td>
                <td align="char" char="." rowspan="1" colspan="1">9</td>
                <td align="char" char="." rowspan="1" colspan="1">4</td>
                <td align="char" char="." rowspan="1" colspan="1">9</td>
                <td align="char" char="." rowspan="1" colspan="1">4</td>
                <td align="char" char="." rowspan="1" colspan="1">0.07</td>
                <td align="left" rowspan="1" colspan="1">KIAA1671</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Q86T24</td>
                <td align="char" char="." rowspan="1" colspan="1">65</td>
                <td align="char" char="." rowspan="1" colspan="1">75,065</td>
                <td align="char" char="." rowspan="1" colspan="1">1</td>
                <td align="char" char="." rowspan="1" colspan="1">1</td>
                <td align="char" char="." rowspan="1" colspan="1">1</td>
                <td align="char" char="." rowspan="1" colspan="1">1</td>
                <td align="char" char="." rowspan="1" colspan="1">0.04</td>
                <td align="left" rowspan="1" colspan="1">ZBTB33</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">O14867</td>
                <td align="char" char="." rowspan="1" colspan="1">59</td>
                <td align="char" char="." rowspan="1" colspan="1">83,844</td>
                <td align="char" char="." rowspan="1" colspan="1">2</td>
                <td align="char" char="." rowspan="1" colspan="1">1</td>
                <td align="char" char="." rowspan="1" colspan="1">2</td>
                <td align="char" char="." rowspan="1" colspan="1">1</td>
                <td align="char" char="." rowspan="1" colspan="1">0.04</td>
                <td align="left" rowspan="1" colspan="1">BACH1</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">O43318</td>
                <td align="char" char="." rowspan="1" colspan="1">55</td>
                <td align="char" char="." rowspan="1" colspan="1">67,895</td>
                <td align="char" char="." rowspan="1" colspan="1">4</td>
                <td align="char" char="." rowspan="1" colspan="1">2</td>
                <td align="char" char="." rowspan="1" colspan="1">4</td>
                <td align="char" char="." rowspan="1" colspan="1">2</td>
                <td align="char" char="." rowspan="1" colspan="1">0.10</td>
                <td align="left" rowspan="1" colspan="1">TAB 1</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">O43164</td>
                <td align="char" char="." rowspan="1" colspan="1">39</td>
                <td align="char" char="." rowspan="1" colspan="1">79,192</td>
                <td align="char" char="." rowspan="1" colspan="1">3</td>
                <td align="char" char="." rowspan="1" colspan="1">1</td>
                <td align="char" char="." rowspan="1" colspan="1">3</td>
                <td align="char" char="." rowspan="1" colspan="1">1</td>
                <td align="char" char="." rowspan="1" colspan="1">0.04</td>
                <td align="left" rowspan="1" colspan="1">Praja2</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Q04721</td>
                <td align="char" char="." rowspan="1" colspan="1">21</td>
                <td align="char" char="." rowspan="1" colspan="1">279,082</td>
                <td align="char" char="." rowspan="1" colspan="1">5</td>
                <td align="char" char="." rowspan="1" colspan="1">2</td>
                <td align="char" char="." rowspan="1" colspan="1">3</td>
                <td align="char" char="." rowspan="1" colspan="1">1</td>
                <td align="char" char="." rowspan="1" colspan="1">0.01</td>
                <td align="left" rowspan="1" colspan="1">Notch 2</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Q9BXU1</td>
                <td align="char" char="." rowspan="1" colspan="1">20</td>
                <td align="char" char="." rowspan="1" colspan="1">116,647</td>
                <td align="char" char="." rowspan="1" colspan="1">7</td>
                <td align="char" char="." rowspan="1" colspan="1">1</td>
                <td align="char" char="." rowspan="1" colspan="1">3</td>
                <td align="char" char="." rowspan="1" colspan="1">1</td>
                <td align="char" char="." rowspan="1" colspan="1">0.03</td>
                <td align="left" rowspan="1" colspan="1">SgK396</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">O14641</td>
                <td align="char" char="." rowspan="1" colspan="1">17</td>
                <td align="char" char="." rowspan="1" colspan="1">79,184</td>
                <td align="char" char="." rowspan="1" colspan="1">5</td>
                <td align="char" char="." rowspan="1" colspan="1">1</td>
                <td align="char" char="." rowspan="1" colspan="1">5</td>
                <td align="char" char="." rowspan="1" colspan="1">1</td>
                <td align="char" char="." rowspan="1" colspan="1">0.04</td>
                <td align="left" rowspan="1" colspan="1">DSH homolog 2</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">O15355</td>
                <td align="char" char="." rowspan="1" colspan="1">16</td>
                <td align="char" char="." rowspan="1" colspan="1">59,919</td>
                <td align="char" char="." rowspan="1" colspan="1">9</td>
                <td align="char" char="." rowspan="1" colspan="1">2</td>
                <td align="char" char="." rowspan="1" colspan="1">6</td>
                <td align="char" char="." rowspan="1" colspan="1">2</td>
                <td align="char" char="." rowspan="1" colspan="1">0.11</td>
                <td align="left" rowspan="1" colspan="1">PPM1G</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="embj201593374-note-0001">
              <p>The table represents the summary of four independent 3ÃFlagâtagged Fbxl17 immunoprecipitation experiments followed by liquid chromatographyâmass spectrometry (LC/MS). Identified interacting proteins in Fbxl17 were filtered using LC/MS data from 8 independent analyses of unrelated Fâbox proteins 3ÃFlag immunoprecipitations. Results were scored according to confidence of identification and a Mascot Mowse cutoff score of 50 was established. Proteins identified with a Mascot cutoff score below 50 in more than one biological replicate are also reported.</p>
            </fn>
          </table-wrap-foot>
          <permissions>
            <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
          </permissions>
        </table-wrap>
        <p>Since a single substrate might be targeted by different ligases (like in the case of Î²âTrCP1 and Î²âTrCP2; betaâtransducin repeat containing E3 ubiquitin protein ligase 1 and 2) (Guardavaccaro <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0018" ref-type="ref">2003</xref>), we screened a panel of Flagâtagged Fâbox proteins isolated from HEK293T cells for the binding to Sufu. We detected Sufu only in Fbxl17 coâimmunoprecipitates (FigÂ <xref rid="embj201593374-fig-0001" ref-type="fig">1</xref>A), whereas all Fâbox proteins bound to Skp1.</p>
        <fig fig-type="Figure" xml:lang="en" id="embj201593374-fig-0001" orientation="portrait" position="float">
          <label>Figure 1</label>
          <caption>
            <title>Fbxl17 interacts with Sufu and regulates Sufu levels</title>
            <p>
<list list-type="simple" id="embj201593374-list-0002"><list-item><label>A</label><p>Detection of Sufu and Skp1 after immunoprecipitation of the indicated Flagâtagged Fâbox proteins (FBPs). An empty vector (EV) was used as a negative control. HEK293T cells were treated with MLN4924 (2Â Î¼M) for 5Â h prior to collection. Representative image of three independent experiments is shown.</p></list-item><list-item><label>B, C</label><p>Immunoprecipitation of endogenous Sufu from PC3 (B) and DAOY cells (C) transfected with either an empty vector (EV) or Mycâtagged Fbxl17. Nonspecific rabbit immunoglobulin G (IgG) was used as a negative control. Detection of light chains of immunoglobulin (IgG) was used to assess the amount of IgG used for each immunoprecipitation reaction. Treatment with MLN4925 (2Â Î¼M) was started 5Â h before the cell collection.</p></list-item><list-item><label>D</label><p>Quantification of Fbxl17 mRNA levels in PC3 and DAOY cells transfected with a nontargeting siRNA (Control) or two siRNAs to Fbxl17 (1) and (2). The cells were serumâstarved for 24Â h in serumâreduced medium and treated with SAG (100Â nM) for 24Â h prior to collection. Data are shown as meanÂ Â±Â SEM.</p></list-item><list-item><label>E</label><p>Sufu protein levels in PC3 and DAOY cells treated as in (D). GAPDH was used as a loading control. Representative image of three independent experiments is shown.</p></list-item><list-item><label>F</label><p>Sufu protein levels in PC3 and DAOY cells infected with an empty backbone retrovirus (EV) or a retrovirus expressing Mycâtagged Fbxl17. Representative image from three independent experiments is shown.</p></list-item><list-item><label>G</label><p>Detection of Sufu protein levels following cycloheximide (CHX) treatment for the indicated hours, and Fbxl17 depletion using two different siRNAs (HrsÂ =Â h). Representative image of two independent experiments is shown.</p></list-item></list>
</p>
          </caption>
          <graphic id="nlm-graphic-5" xlink:href="EMBJ-35-1400-g002"/>
        </fig>
        <p>To confirm that the binding between Fbxl17 and Sufu was not due to spurious interaction due to Fbxl17 overexpression, we isolated endogenous Sufu after treating cells with an inhibitor of NAE (Nedd8âactivating enzyme) (MLN4924) (Soucy <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0054" ref-type="ref">2009</xref>). This treatment blocks cullin neddylation required for the activity of SCF ubiquitin ligases (Ohh <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0039" ref-type="ref">2002</xref>). Using this approach, we detected endogenous Fbxl17 in Sufu immunoprecipitates (FigÂ <xref rid="embj201593374-fig-0001" ref-type="fig">1</xref>B and C, lane 2) using an antibody against the endogenous protein. To confirm the validity of the antibody for immunoprecipitation and Western blot, we compared Fbxl17 detected in Sufuâimmunoprecipitated material to an Fbxl17, which was exogenously expressed (FigÂ <xref rid="embj201593374-fig-0001" ref-type="fig">1</xref>B and C, lane 3). The interaction between endogenous Fbxl17 and Sufu was validated in PC3 (human prostate cancer cell line) and DAOY (medulloblastoma cancer cell line) (FigÂ <xref rid="embj201593374-fig-0001" ref-type="fig">1</xref>B and C), indicating that Fbxl17 and Sufu interact specifically, physiologically, and in different cell lines.</p>
        <p>To assess whether Fbxl17 affects Sufu levels, we measured the protein levels of Sufu in PC3 and DAOY cells upon Fbxl17 depletion using short interfering RNA (siRNA) (FigÂ <xref rid="embj201593374-fig-0001" ref-type="fig">1</xref>D). Fbxl17 depletion by two siRNAs increased Sufu protein levels in both PC3 and DAOY (FigÂ <xref rid="embj201593374-fig-0001" ref-type="fig">1</xref>E). Opposite to this, exogenous expression of Mycâtagged Fbxl17 led to the downregulation of Sufu protein in both cell lines (FigÂ <xref rid="embj201593374-fig-0001" ref-type="fig">1</xref>F). Sufu protein levels upon either Fbxl17 depletion or overexpression were quantified (FigÂ <xref rid="embj201593374-fig-0001ev" ref-type="fig">EV1</xref>A and B). Sufu mRNA levels remained unchanged upon the modulation of Fbxl17 levels (FigÂ <xref rid="embj201593374-fig-0001ev" ref-type="fig">EV1</xref>C and D), suggesting that Sufu is regulated by Fbxl17 through a postâtranslational mechanism. To exclude other mechanisms of control on Sufu by Fbxl17, we measured Sufu halfâlife in cells where Fbxl17 was depleted using two different siRNAs. While Sufu halfâlife was approximately 6Â h in cells treated with a nontargeting siRNA, this increased to more than 12Â h in Fbxl17âdepleted cells (FigÂ <xref rid="embj201593374-fig-0001" ref-type="fig">1</xref>G). Protein levels of Sufu, upon CHX treatment, were quantified in FigÂ <xref rid="embj201593374-fig-0001ev" ref-type="fig">EV1</xref>E and mRNA levels of Fbxl17 were measured by qPCR in FigÂ <xref rid="embj201593374-fig-0001ev" ref-type="fig">EV1</xref>F.</p>
        <fig fig-type="Figure" xml:lang="en" specific-use="collapsible" id="embj201593374-fig-0001ev" orientation="portrait" position="float">
          <label>Figure EV1</label>
          <caption>
            <title>Fbxl17 modulates Sufu protein levels, without affecting Sufu <styled-content style="fixed-case">mRNA</styled-content>
</title>
            <p>
<list list-type="alpha-upper" id="embj201593374-list-0010"><list-item><p>Relative abundance of Sufu protein levels in PC3 and DAOY cells reported in FigÂ <xref rid="embj201593374-fig-0001" ref-type="fig">1</xref>E (meanÂ Â±Â SEM from three independent experiments, *<italic>P</italic>Â &lt;Â 0.05; **<italic>P</italic>Â &lt;Â 0.005).</p></list-item><list-item><p>Relative abundance of Sufu protein levels in PC3 and DAOY cells reported in FigÂ <xref rid="embj201593374-fig-0001" ref-type="fig">1</xref>F (meanÂ Â±Â SEM from three independent experiments, **<italic>P</italic>Â &lt;<italic>Â </italic>0.005).</p></list-item><list-item><p>Sufu mRNA levels in PC3 and DAOY cells transfected with either a nontargeting siRNA (Control) or two siRNAs to Fbxl17 (1) and (2) (meanÂ Â±Â SEM).</p></list-item><list-item><p>Sufu mRNA levels after the transfection of the indicated cell lines with an empty vector (EV) or a vector expressing MycâFbxl17 (meanÂ Â±Â SEM).</p></list-item><list-item><p>Relative abundance of Sufu protein levels in HeLa cells reported FigÂ <xref rid="embj201593374-fig-0001" ref-type="fig">1</xref>G. Data are normalized relative to 0Â h (Hrs) of CHX (cycloheximide) treatment.</p></list-item><list-item><p>Fbxl17 mRNA levels in HeLa cells treated as in FigÂ <xref rid="embj201593374-fig-0001" ref-type="fig">1</xref>G (meanÂ Â±Â SEM).</p></list-item></list>
</p>
          </caption>
          <graphic id="nlm-graphic-7" xlink:href="EMBJ-35-1400-g003"/>
        </fig>
      </sec>
      <sec id="embj201593374-sec-0004">
        <title>SCF<sup>Fbxl17</sup> mediates Sufu polyubiquitylation</title>
        <p>In order to assess whether Fbxl17 is directly targeting Sufu, we measured Sufu polyubiquitylation in cells where Fbxl17 was depleted by siRNA. Remarkably, Sufu polyubiquitylation was completely abolished by Fbxl17 siRNA in both DAOY and 293T cells (FigÂ <xref rid="embj201593374-fig-0002" ref-type="fig">2</xref>AâC), supporting the role of Fbxl17 as the major physiological ubiquitin ligase for Sufu in different cellular systems.</p>
        <fig fig-type="Figure" xml:lang="en" id="embj201593374-fig-0002" orientation="portrait" position="float">
          <label>Figure 2</label>
          <caption>
            <title>
<styled-content style="fixed-case">SCF<sup>F</sup></styled-content>
<sup>bxl17</sup> mediates Sufu polyubiquitylation</title>
            <p>
<list list-type="alpha-upper" id="embj201593374-list-0003"><list-item><p>Detection of polyubiquitylated species of endogenous Sufu coâimmunopurified from DAOY cells transfected with Mycâtagged ubiquitin (Ub) either in the presence of nontargeting siRNA (Control) or in the presence of two siRNAs against Fbxl17 (1) and (2). MG132 (10Â Î¼M) was added in all samples.</p></list-item><list-item><p>Detection of polyubiquitylated species of Sufu upon coâtransfection of HEK293T cells with HAâtagged Sufu and Mycâtagged ubiquitin (Ub) either in the presence of nontargeting siRNA (Control) or in the presence of two siRNAs against Fbxl17 (1) and (2). MG132 (10Â Î¼M) was added in all samples.</p></list-item><list-item><p>Fbxl17 mRNA relative levels in DAOY and HEK293T cells upon Fbxl17 depletion with either a nontargeting siRNA (Control) or two siRNAs to Fbxl17 (1) and (2). Data are shown as meanÂ Â±Â SEM.</p></list-item><list-item><p>Detection of ubiquitylated Sufu coâimmunoprecipitated from HEK293T cells coâtransfected with HAâtagged Sufu, Mycâubiquitin (Ub) along with either Flagâtagged Fbxl17 wild type (WT) or a mutant lacking the Fâbox domain (Fbxl17ÎF). MG132 (10Â Î¼M) was added in all samples.</p></list-item><list-item><p>Detection of ubiquitylated Sufu coâimmunoprecipitated from HEK293T cells coâtransfected with Mycâtagged ubiquitin (Ub), Flagâtagged Fbxl17, and HAâtagged Sufu WT or Sufu mutant K257R. MG132 (10Â Î¼M) was added in all samples.</p></list-item></list>
</p>
          </caption>
          <graphic id="nlm-graphic-9" xlink:href="EMBJ-35-1400-g004"/>
        </fig>
        <p>Deletion mapping analysis showed that the carboxyl terminus of Fbxl17 containing the leucine zipper motif is essential for Sufu binding, whereas the amino terminus and the Fâbox motif of Fbxl17 were dispensable for Sufu recruitment (FigÂ <xref rid="embj201593374-fig-0002ev" ref-type="fig">EV2</xref>A and B). To confirm that polyubiquitylation of Sufu was due to Fbxl17 activity, we measured Sufu polyubiquitylation using an Fbxl17 lacking the Fâbox domain (that is still able to interact with Sufu, but not with Skp1; FigÂ <xref rid="embj201593374-fig-0002ev" ref-type="fig">EV2</xref>B). Expression of exogenous Fbxl17 promoted Sufu polyubiquitylation, whereas an Fbxl17 mutant lacking the Fâbox failed to do so, indicating that the formation of the SCF is not a prerequisite for the binding of Fbxl17 to its substrates, but required for ubiquitylation (FigÂ <xref rid="embj201593374-fig-0002" ref-type="fig">2</xref>D).</p>
        <fig fig-type="Figure" xml:lang="en" specific-use="collapsible" id="embj201593374-fig-0002ev" orientation="portrait" position="float">
          <label>Figure EV2</label>
          <caption>
            <title>Sufu polyubiquitylation requires interaction with the carboxyl terminus of Fbxl17</title>
            <p>
<list list-type="alpha-upper" id="embj201593374-list-0011"><list-item><p>SchemeÂ representing the mapping strategy to identify Fbxl17 region required for Sufu recognition. The Fâbox is highlighted in black and the leucineârich repeats (LRR) in yellow.</p></list-item><list-item><p>Detection of Sufu and Skp1 after immunoprecipitation of Mycâtagged Fbxl17âtruncated fragments, as indicated. An empty vector (EV) was used as a negative control. HEK293T cells were treated with MLN4924 (2Â Î¼M) for 5Â h prior to collection.</p></list-item><list-item><p>
<italic>In vitro</italic> ubiquitylation assay of Sufu WT and Sufu mutant K257R by Fbxl17âtruncated version 318â701. All proteins were synthesized <italic>inÂ vitro</italic> using a T7âcoupled reticulocyte lysate system and incubated for the indicated times. Arrow indicates a nonspecific band detected in reticulocyte lysates.</p></list-item></list>
</p>
          </caption>
          <graphic id="nlm-graphic-11" xlink:href="EMBJ-35-1400-g005"/>
        </fig>
        <p>Furthermore, we observed that Fbxl17 used the lysine 257 of Sufu as a preferential attachment site for ubiquitin, since the polyubiquitylation of Sufu mutant K257R was impaired (FigÂ <xref rid="embj201593374-fig-0002" ref-type="fig">2</xref>E). Using reticulocyte lysates, we reconstituted the components of the SCF<sup>Fbxl17</sup> and Sufu in an <italic>inÂ vitro</italic> reaction, as previously done (Peschiaroli <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0042" ref-type="ref">2006</xref>). We observed ubiquitylation of Sufu wild type (WT), while the Sufu K257R was ubiquitylated to a reduced extent (FigÂ <xref rid="embj201593374-fig-0002ev" ref-type="fig">EV2</xref>C). These findings explain the increased halfâlife of Sufu K257R mutant reported elsewhere (Yue <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0067" ref-type="ref">2009</xref>) and suggest that Fâbox proteins might have preferential ubiquitin attachment sites on substrates.</p>
      </sec>
      <sec id="embj201593374-sec-0005">
        <title>Fbxl17âSufu interaction is impaired by Sufu phosphorylation and favored by the presence of Gli</title>
        <p>To gain insights into the details of Fbxl17 recognition of Sufu, we used Sufuâtruncated mutants and measured binding to Fbxl17. A region of Sufu encompassing amino acids 350â425 was found to be sufficient for the binding to Fbxl17 (FigÂ <xref rid="embj201593374-fig-0003ev" ref-type="fig">EV3</xref>AâC). Phosphorylation is a common mechanism used by Fâbox proteins for substrate recognition; however, in the case of Fbxls, phosphorylation could also block substrate recognition (Kuchay <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0032" ref-type="ref">2013</xref>; Skaar <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0051" ref-type="ref">2013</xref>).</p>
        <fig fig-type="Figure" xml:lang="en" specific-use="collapsible" id="embj201593374-fig-0003ev" orientation="portrait" position="float">
          <label>Figure EV3</label>
          <caption>
            <title>Systematic analysis of Sufu mode of interaction to Fbxl17</title>
            <p>
<list list-type="alpha-upper" id="embj201593374-list-0012"><list-item><p>Schematic representation of Sufuâtruncated mutants used to identify Sufu region required for Fbxl17 recognition. The black square delimitates the minimal binding region 350â425.</p></list-item><list-item><p>Detection of Mycâtagged Fbxl17 after immunoprecipitation of HAâSufuâtruncated fragments, as indicated in (A). An empty vector (EV) was used as a negative control. HEK293T cells were treated with MLN4924 (2Â Î¼M) for 5Â h prior to collection.</p></list-item><list-item><p>Detection of Mycâtagged Fbxl17 binding to HAâtagged Sufu deletion construct 350â425 in HEK293T cells. Transfection of an empty vector (EV) was used as a negative control for immunoprecipitation. Cells were treated with MLN4924 (2Â Î¼M) for 5Â h prior to collection.</p></list-item><list-item><p>Detection of Mycâtagged Fbxl17 binding to immunoprecipitated HAâtagged Sufu wild type (WT), Sufu S352F, or Sufu S352D. An empty vector (EV) was used as a negative control. HEK293T cells were treated with MLN4924 (2Â Î¼M) for 5Â h prior to collection.</p></list-item><list-item><p>Detection of Flagâtagged Gli1 and Mycâtagged Fbxl17 after immunoprecipitation of HAâtagged Sufu WT or Sufu S342/6A and S342/6D, as indicated. HEK293T cells were treated with MLN4924 (2Â Î¼M) for 5Â h prior to collection.</p></list-item><list-item><p>Detection of Mycâtagged Fbxl17 after immunoprecipitation of the indicated HAâSufu point mutants in HEK293T cells. Cells were treated with MLN4924 (2Â Î¼M) for 5Â h prior to collection.</p></list-item></list>
</p>
          </caption>
          <graphic id="nlm-graphic-13" xlink:href="EMBJ-35-1400-g007"/>
        </fig>
        <p>Sufu WT was unable to bind Fbxl17 efficiently as the Sufu 350â484âtruncated mutant (FigÂ <xref rid="embj201593374-fig-0003ev" ref-type="fig">EV3</xref>B), suggesting the presence of a phosphorylation event on Sufu, that might prevent Fbxl17 binding outside of the minimal binding region. Thus, we systematically mutagenized all the serine and threonine residues to alanine on Sufu between the residues 1 and 350. While the majority of sites did not affect the binding of Fbxl17 to Sufu (FigÂ <xref rid="embj201593374-fig-0003ev" ref-type="fig">EV3</xref>E and F), a mutant of Sufu in which the S342 and S346 residues were changed to alanine (A) increased binding to Fbxl17 (FigÂ <xref rid="embj201593374-fig-0003" ref-type="fig">3</xref>A). Substitution of S342 and S346 to D (S342/6D) to mimic phosphorylation decreased recognition by Fbxl17 (FigÂ <xref rid="embj201593374-fig-0003" ref-type="fig">3</xref>A). These data are consistent with the increased stabilization of Sufu detected upon the phosphorylation of these residues by PKA (protein kinase A) and GSK3Î² (glycogen synthase kinase 3Î²) (Chen <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0005" ref-type="ref">2011</xref>).</p>
        <fig fig-type="Figure" xml:lang="en" id="embj201593374-fig-0003" orientation="portrait" position="float">
          <label>Figure 3</label>
          <caption>
            <title>Fbxl17âSufu interaction is impaired by Sufu phosphorylation and favored by the presence of Gli</title>
            <p>
<list list-type="alpha-upper" id="embj201593374-list-0004"><list-item><p>Detection of Mycâtagged Fbxl17 after immunoprecipitation of HAâtagged Sufu WT or Sufu S342/6A and S342/6D, as indicated. HEK293T cells were treated with MLN4924 (2Â Î¼M) for 5Â h prior to collection.</p></list-item><list-item><p>Detection of Flagâtagged Gli1 and Mycâtagged Fbxl17 binding to immunoprecipitated HAâtagged Sufu wild type (WT) or to Sufu S352F. An empty vector (EV) was used as a negative control. HEK293T cells were treated with MLN4924 (2Â Î¼M) for 5Â h prior to collection.</p></list-item><list-item><p>Detection of Sufu phosphorylated on S352/T353 after immunoprecipitation of HAâtagged Sufu WT and Sufu 351â353 AAA, as indicated.</p></list-item><list-item><p>Detection of Mycâtagged Fbxl17 binding to Sufu fullâlength (FL) or to the following Sufu peptides: Sufu 340â360 (APSRKDSLESDSSTAIIPHEL); Sufu 340â360 [S352P/T353P] (phosphorylated on the residues S352 and T353); Sufu 351â372 (SSTAIIPHELIRTRQLESVHLK).</p></list-item><list-item><p>Detection of HAâtagged Sufu binding to a Mycâtagged Fbxl17 construct encompassing the residues 318â701 (corresponding to the Fâbox motif and Câterminus region) assessed by <italic>inÂ vitro</italic> binding assay. Both proteins were synthesized <italic>inÂ vitro</italic> using a T7âcoupled reticulocyte lysate system.</p></list-item><list-item><p>Detection of ubiquitylated Sufu immunoprecipitated from HEK293T cells coâtransfected with HAâtagged ubiquitin (Ub), Mycâtagged Fbxl17, and Flagâtagged Gli1. MG132 (10Â Î¼M) was added in all samples.</p></list-item><list-item><p>Detection of Flagâtagged Gli1 binding to Mycâtagged Fbxl17 coâimmunoprecipitated from HEK293T cells transfected with a nontargeting siRNA (Control) or two siRNA to Sufu (1) and (2), as indicated.</p></list-item></list>
</p>
          </caption>
          <graphic id="nlm-graphic-15" xlink:href="EMBJ-35-1400-g006"/>
        </fig>
        <p>Within the minimal binding region of Sufu to Fbxl17, Sufu has been found phosphorylated on S352 (Hsu <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0021" ref-type="ref">2011</xref>). A natural occurring mutation (S352F) abolishing S352 phosphorylation has been described in the medulloblastoma of patients affected by Gorlin syndrome (Smith <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0053" ref-type="ref">2014</xref>). Therefore, we tested Fbxl17 binding to Sufu S352F. The Sufu S352F substitution increased Fbxl17 binding (FigÂ <xref rid="embj201593374-fig-0003" ref-type="fig">3</xref>B); on the contrary, a mutant of Sufu where the S352 residue was changed to aspartate (D) to mimic the phosphorylation showed reduced binding to Fbxl17 (FigÂ <xref rid="embj201593374-fig-0003ev" ref-type="fig">EV3</xref>D). We performed LC/MS analysis to obtain high coverage of Sufu modifications and identified multiple phosphorylation sites in this region (<xref rid="embj201593374-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S1A</xref>). Furthermore, we generated a phosphoâspecific antibody against a peptide of Sufu containing both S352 and T353 residues phosphorylated. The antibody recognizes Sufu WT, indicating that S352 and T353 are phosphorylated <italic>inÂ vivo</italic>, but did not recognize a mutant of Sufu where S352 and T353 were substituted to alanine (S351âT353AAA) (FigÂ <xref rid="embj201593374-fig-0003" ref-type="fig">3</xref>C).</p>
        <p>Given the crucial role of residues S342, S346, and S352 for Fbxl17âSufu interaction, we tested whether Fbxl17 is able to bind to a linear peptide encompassing amino acids 340â360 (with and without the phosphorylation of S352/T353 residues) and 351â372. Independently of the phosphorylation status of S352 residue, Fbxl17 purified from the cells did not bind to Sufu peptides, but interacted with fullâlength Sufu <italic>inÂ vitro</italic>, indicating that a linear sequence is not sufficient for Fbxl17 binding (FigÂ <xref rid="embj201593374-fig-0003" ref-type="fig">3</xref>D). Additionally, Fbxl17 and Sufu synthesized <italic>inÂ vitro</italic> were able to bind, pinpointing that the interaction is direct and independent of postâtranslational modifications induced by Hh signaling (FigÂ <xref rid="embj201593374-fig-0003" ref-type="fig">3</xref>E).</p>
        <p>Fbxws utilize the WD40 domain to interact with phosphorylated linear degradation sequences; however in the case of the Fbxls, the leucine zipper motif is contacting a larger surface and could require the presence of cofactors (Hao <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0019" ref-type="ref">2005</xref>; Xing <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0065" ref-type="ref">2013</xref>). The conformation of Sufu is regulated by Gli binding and SufuâGli interaction requires an intact tertiary structure of Sufu (Cherry <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0007" ref-type="ref">2013</xref>; Zhang <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0069" ref-type="ref">2013</xref>). Thus, we asked whether Gli1 acts as a cofactor modulating the interaction between Fbxl17 and Sufu <italic>inÂ vivo</italic>. Remarkably, Fbxl17 polyubiquitylation of endogenous Sufu was favored by the presence of exogenous Gli1 that promoted an increased binding of Fbxl17 to Sufu and the subsequent polyubiquitylation (FigÂ <xref rid="embj201593374-fig-0003" ref-type="fig">3</xref>F). To assess that the latter was due to the direct interaction between Fbxl17 and Sufu, we depleted Sufu using two different siRNA and tested the binding of Gli1 to Fbxl17. Sufu depletion abolished the binding of Gli1 to Fbxl17, indicating that Sufu bridges the interaction between Fbxl17 and Gli1 <italic>inÂ vivo</italic> (FigÂ <xref rid="embj201593374-fig-0003" ref-type="fig">3</xref>G).</p>
      </sec>
      <sec id="embj201593374-sec-0006">
        <title>Sufu ubiquitylation by Fbxl17 allows Gli dissociation for Hedgehog signaling activation</title>
        <p>It is not well understood how Sufu is released from Gli1 for full Hh pathway activation. We speculated that Fbxl17 could mediate the release by promoting Sufu polyubiquitylation and degradation. To assess the latter, we analyzed Sufu protein levels in mouse embryonic fibroblasts (MEFs) that express the receptor Ptch1 (<italic>Ptch1</italic>
<sup>+/+</sup>), MEFs with heterozygous loss of <italic>Ptch1</italic> (<italic>Ptch1</italic>
<sup>+/â</sup>), and MEFs deficient in <italic>Ptch1</italic> (<italic>Ptch1</italic>
<sup>â/â</sup>), which have constitutive Hh signaling (Taipale <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0056" ref-type="ref">2000</xref>). Strikingly, MEFs <italic>Ptch1</italic>
<sup>â/â</sup> and <italic>Ptch1</italic>
<sup>+/â</sup> cells showed a decrease in Sufu levels corresponding to the degree of Ptch loss and the consequent Hh activation. Sufu levels were reduced in <italic>Ptch1</italic>
<sup>â/â</sup> and less significantly in <italic>Ptch1</italic>
<sup>+/â</sup>, while remained unaffected in <italic>Ptch1</italic>
<sup>+/+</sup>, indicating that Fbxl17 is acting downstream of Ptch and Smo. Low levels of Sufu present in MEFs <italic>Ptch1</italic>
<sup>+/â</sup> and MEFs <italic>Ptch1</italic>
<sup>â/â</sup> were restored to levels comparable to <italic>Ptch1</italic>
<sup>+/+</sup> by Fbxl17 depletion (FigÂ <xref rid="embj201593374-fig-0004" ref-type="fig">4</xref>A and B). Furthermore, MEFs <italic>Ptch1</italic>
<sup>â/â</sup> lacking Fbxl17 presented low transcription levels of Hh target genes such as Gli1 and Bcl2 due to a negative effect that Sufu accumulation exerts on Gliâmediated target gene expression (FigÂ <xref rid="embj201593374-fig-0004" ref-type="fig">4</xref>C and D).</p>
        <fig fig-type="Figure" xml:lang="en" id="embj201593374-fig-0004" orientation="portrait" position="float">
          <label>Figure 4</label>
          <caption>
            <title>Sufu ubiquitylation by Fbxl17 allows Gli dissociation for Hedgehog signaling activation</title>
            <p>
<list list-type="alpha-upper" id="embj201593374-list-0005"><list-item><p>Sufu protein levels in mouse embryonic fibroblasts (MEFs) <italic>Ptch1</italic>
<sup>+/+</sup>, <italic>Ptch1</italic>
<sup>+/â</sup>, and <italic>Ptch1</italic>
<sup>â/â</sup> transfected with a nontargeting siRNA (Control) or two siRNAs targeting mouse Fbxl17 (1) and (2).</p></list-item><list-item><p>Quantification of Fbxl17 mRNA levels in MEFs <italic>Ptch1</italic>
<sup>+/+</sup>, <italic>Ptch1</italic>
<sup>+/â</sup>, and <italic>Ptch1</italic>
<sup>â/â</sup> transfected as in (A). Data are shown as meanÂ Â±Â SEM.</p></list-item><list-item><p>Analysis of Gli1 mRNA levels in MEFs <italic>Ptch1</italic>
<sup>+/+</sup> and <italic>Ptch1</italic>
<sup>â/â</sup> upon Fbxl17 depletion using two different siRNAs (meanÂ Â±Â SEM from three independent experiments, ***<italic>P</italic>Â &lt;<italic>Â </italic>0.0005, unpaired <italic>t</italic>âtest).</p></list-item><list-item><p>Analysis of Bcl2 mRNA levels in MEFs <italic>Ptch1</italic>
<sup>+/+</sup> and <italic>Ptch1</italic>
<sup>â/â</sup> upon Fbxl17 depletion using two different siRNAs (meanÂ Â±Â SEM from three independent experiments, **<italic>P</italic>Â &lt;Â 0.005, ***<italic>P</italic>Â &lt;<italic>Â </italic>0.0005, unpaired <italic>t</italic>âtest).</p></list-item><list-item><p>Detection of Flagâtagged Gli1 binding to HAâtagged Sufu in MEFs <italic>Ptch1</italic>
<sup>â/â</sup> upon expression of Mycâtagged Fbxl17, or Fbxl17 depletion by two siRNAs. For each condition, 200Â Î¼g of wholeâcell lysate was immunoprecipitated.</p></list-item><list-item><p>Immunostaining of Fbxl17 using antiâMyc antibody in <italic>Ptch1</italic>
<sup>â/â</sup> MEFs stably transduced with a pBABE vector expressing Fbxl17 tagged with Myc either at the Nâterminus [Myc(N)âFbxl17] or at the Câterminus [Myc(C)âFbxl17]. Scale bars: 20Â Î¼m.</p></list-item><list-item><p>Detection of Fbxl17 using antiâMyc antibody in <italic>Ptch1</italic>
<sup>â/â</sup> MEFs stably expressing Myc(N)âFbxl17 (Fbxl17 tagged at the Nâterminus) and Myc(C)âFbxl17 (Fbxl17 tagged at the Câterminus).</p></list-item><list-item><p>Detection of HAâtagged Fbxl17 binding to endogenous Sufu immunoprecipitated from cytoplasmic and nuclear extracts from <italic>Ptch1</italic>
<sup>â/â</sup> MEFs. Asterisk (*) indicates a nonspecific band. Identification of cytoplasmic and nuclear fractions was performed by lamin A/C and GAPDH detection.</p></list-item></list>
</p>
          </caption>
          <graphic id="nlm-graphic-17" xlink:href="EMBJ-35-1400-g008"/>
        </fig>
        <p>Considering the defects observed in pathway activation upon Fbxl17 depletion in MEFs <italic>Ptch1</italic>
<sup>â/â</sup> cells and that Fbxl17 preferentially binds to the SufuâGli complex, we speculated that Fbxl17 polyubiquitylation favors SufuâGli complex dissociation to allow the need to be substituted with Hh pathway activation. Indeed, Fbxl17 overexpression induced Sufu degradation and Gli1 release, whereas the depletion of Fbxl17 in MEFs <italic>Ptch1</italic>
<sup>â/â</sup> led to an accumulation of SufuâGli1 complexes (FigÂ <xref rid="embj201593374-fig-0004" ref-type="fig">4</xref>E and <xref rid="embj201593374-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S1B</xref>). Since the polyubiquitylation of SufuÂ precedes degradation, this model is in accordance with previous findings on SufuâGli complex formation and dissociation (Tukachinsky <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0061" ref-type="ref">2010</xref>).</p>
        <p>Finally, we addressed where the degradation of Sufu takes place in cells MEFs <italic>Ptch1</italic>
<sup>â/â</sup> where the pathway is constitutively activated. Due to the lack of an antibody detecting endogenous Fbxl17 by immunofluorescence, we stably expressed Fbxl17 using a retroviral system that maintains physiological levels of protein expression. To avoid localization artifacts, we expressed an Fbxl17 tagged with Myc at the Câterminus and Nâterminus. In both cases, the localization of Fbxl17 in MEFs <italic>Ptch1</italic>
<sup>â/â</sup> was exclusively nuclear (FigÂ <xref rid="embj201593374-fig-0004" ref-type="fig">4</xref>F and G). Furthermore, exogenous Fbxl17 expressed in MEFs <italic>Ptch1</italic>
<sup>â/â</sup> induced downregulation of Sufu in the nucleus, where Fbxl17 interacted with Sufu upon biochemical fractionation of the cytoplasmic and nuclear extracts (FigÂ <xref rid="embj201593374-fig-0004" ref-type="fig">4</xref>H). Since phosphorylation of Sufu on S342/S346 promotes ciliary retention of Sufu (Chen <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0005" ref-type="ref">2011</xref>), these data are in accordance with a model where Sufu dephosphorylation promotes the localization outside the cilium and ubiquitin mediated proteolysis by Fbxl17.</p>
      </sec>
      <sec id="embj201593374-sec-0007">
        <title>Fbxl17âmediated degradation of Sufu regulates Hh signaling, cancer cell proliferation, and medulloblastoma growth</title>
        <p>Given the relevant role of Fbxl17 in regulating Hh signaling and that Hh signaling activity has been implicated in the proliferation of prostate cancer cell lines (Karhadkar <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0026" ref-type="ref">2004</xref>; Sanchez <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0044" ref-type="ref">2004</xref>), we further tested the effect of Fbxl17 on Hh activation by quantifying Gli1 mRNA levels upon either depletion or expression of Fbxl17 using PC3 cells. Fbxl17 silencing resulted in a decrease in Gli1 mRNA levels (<xref rid="embj201593374-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S2A</xref>), and contrarily, Fbxl17Â expression led to an increase in Gli1 mRNA levels (<xref rid="embj201593374-sup-0001" ref-type="supplementary-material">AppendixÂ FigÂ S2B</xref>). Since proliferation of PC3 cells is in part dependent on Hh signaling pathway (Karhadkar <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0026" ref-type="ref">2004</xref>; Zhang <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0068" ref-type="ref">2007</xref>), we evaluated whether Fbxl17 depletion impairs the prostate cancer cell proliferation. Fbxl17 silencing induced a defective cell proliferation of PC3 cells and this defect was rescued by the reintroduction of Fbxl17 full length in cells depleted of Fbxl17 (<xref rid="embj201593374-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S2CâF</xref>). Moreover, this phenotype was dependent on the accumulation of Sufu, as double siRNA of Fbxl17 and Sufu could restore the proliferation (<xref rid="embj201593374-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S3AâD</xref>).</p>
        <p>A more direct role of Hh pathway has been established in the pathogenesis of medulloblastoma characterized by the presence of mutations in central components of Hh signaling (Kool <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0030" ref-type="ref">2014</xref>); therefore, we tested whether the Fbxl17âSufu axis operates in medulloblastoma cancer cells. DAOY human medulloblastoma cells have been reported to be responsive to Hh signaling modulation (Gotschel <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0017" ref-type="ref">2013</xref>). DAOY cells responded to Smo activation (using SAG; Smo agonist) or inhibition (using cyclopamine; Smo antagonist) by upregulating or downregulating Gli1 mRNA levels, respectively (FigÂ <xref rid="embj201593374-fig-0004ev" ref-type="fig">EV4</xref>A). Silencing of Fbxl17 impaired Gli1 transcription upon SAGâinduced Hh activation (FigÂ <xref rid="embj201593374-fig-0004ev" ref-type="fig">EV4</xref>BâD). Additionally, upon the stimulation of DAOY cells with SHH (Sonic Hedgehog)âconditioned media (FigÂ <xref rid="embj201593374-fig-0004ev" ref-type="fig">EV4</xref>E), Sufu protein levels were reduced (FigÂ <xref rid="embj201593374-fig-0004ev" ref-type="fig">EV4</xref>F). Fbxl17 depletion restored Sufu protein levels after SHHâconditioned media (FigÂ <xref rid="embj201593374-fig-0004ev" ref-type="fig">EV4</xref>F and quantified in <xref rid="embj201593374-fig-0004ev" ref-type="fig">EV4</xref>G), confirming that the downstream activation of Hh signaling pathway depends on Fbxl17âmediated degradation of Sufu in DAOY cells. The observed downregulation of Sufu protein was not due to the variation in Fbxl17 expression upon Hh stimulation. Indeed, the mRNA of Fbxl17 was not affected in DAOY cells upon Hh stimulation with SAG or SHH ligand and Hh inhibition with cyclopamine (FigÂ <xref rid="embj201593374-fig-0004ev" ref-type="fig">EV4</xref>H and I).</p>
        <fig fig-type="Figure" xml:lang="en" specific-use="collapsible" id="embj201593374-fig-0004ev" orientation="portrait" position="float">
          <label>Figure EV4</label>
          <caption>
            <title>Fbxl17 regulates Hh signaling in <styled-content style="fixed-case">DAOY</styled-content> medulloblastoma cells</title>
            <p>
<list list-type="alpha-upper" id="embj201593374-list-0013"><list-item><p>Gli1 mRNA levels in DAOY cells upon the treatment with SAG or cyclopamine. DMSO was used as a control vehicle (meanÂ Â±Â SEM from three independent experiments, **<italic>P</italic>Â &lt;Â 0.005; ***<italic>P</italic>Â &lt;<italic>Â </italic>0.0005).</p></list-item><list-item><p>Gli1 mRNA levels in DAOY cells transfected with nontargeting siRNA (Control) or siRNAs against Fbxl17 (2) and treated with DMSO (meanÂ Â±Â SEM).</p></list-item><list-item><p>Gli1 mRNA levels in DAOY cells transfected as in (B) and treated with SAG (meanÂ Â±Â SEM from three independent experiments, *<italic>P</italic>Â &lt;Â 0.05).</p></list-item><list-item><p>Gli1 mRNA levels in DAOY cells transfected as in (B) and treated with cyclopamine (meanÂ Â±Â SEM).</p></list-item><list-item><p>Gli1 mRNA levels in DAOY cells treated with control medium (â) or medium containing SHH ligand (+) (meanÂ Â±Â SEM from three independent experiments, **<italic>P</italic>Â &lt;Â 0.005).</p></list-item><list-item><p>Detection of Sufu protein levels in DAOY in the presence of a nontargeting siRNA (Control) or two siRNAs to Fbxl17 (1) and (2), after the treatment with control medium (â) or medium containing SHH (Sonic Hedgehog) ligand (+).</p></list-item><list-item><p>Relative abundance of Sufu protein levels detected in (F) (meanÂ Â±Â SEM from three independent experiments, **<italic>P</italic>Â &lt;Â 0.005; ***<italic>P</italic>Â &lt;Â 0.05).</p></list-item><list-item><p>Fbxl17 mRNA levels in DAOY cells upon the treatment with DMSO, SAG, or cyclopamine (meanÂ Â±Â SEM).</p></list-item><list-item><p>Fbxl17 mRNA levels in DAOY cells after the treatment with control medium (â) or medium containing SHH ligand (+) (meanÂ Â±Â SEM).</p></list-item></list>
</p>
          </caption>
          <graphic id="nlm-graphic-19" xlink:href="EMBJ-35-1400-g009"/>
        </fig>
        <p>Similar to PC3 cells, we evaluated whether Fbxl17 depletion impairs DAOY cell proliferation. Proliferation of DAOY cells was hampered by Fbxl17 depletion and stimulated by Fbxl17 reâexpression (FigÂ <xref rid="embj201593374-fig-0005" ref-type="fig">5</xref>A). Fbxl17 siRNA (quantified in FigÂ <xref rid="embj201593374-fig-0005" ref-type="fig">5</xref>B) increased protein levels of Sufu; on the contrary, expression of Fbxl17 corresponded to low protein levels of Sufu in DAOY (FigÂ <xref rid="embj201593374-fig-0005" ref-type="fig">5</xref>C and <xref rid="embj201593374-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S4A</xref>). Importantly, the proliferation defect induced by Fbxl17 depletion was dependent on the accumulation of Sufu, as double siRNA of Fbxl17 and Sufu could restore proliferation in DAOY (FigÂ <xref rid="embj201593374-fig-0005" ref-type="fig">5</xref>DâF and <xref rid="embj201593374-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S4B</xref>).</p>
        <fig fig-type="Figure" xml:lang="en" id="embj201593374-fig-0005" orientation="portrait" position="float">
          <label>Figure 5</label>
          <caption>
            <title>Fbxl17âmediated degradation of Sufu promotes medulloblastoma cell proliferation</title>
            <p>
<list list-type="alpha-upper" id="embj201593374-list-0006"><list-item><p>Cell proliferation of DAOY cells upon Fbxl17 depletion using a nontargeting siRNA (Control), two siRNAs against Fbxl17 (1) and (2) or upon reintroduction of a Mycâtagged Fbxl17 construct in Fbxl17âdepleted DAOY cells using siRNA Fbxl17 (2) (meanÂ Â±Â SEM from three independent experiments, **<italic>P</italic>Â &lt;Â 0.005; ***<italic>P</italic>Â &lt;<italic>Â </italic>0.0005, unpaired <italic>t</italic>âtest).</p></list-item><list-item><p>Quantification of Fbxl17 mRNA levels in DAOY cells transfected with a nontargeting siRNA (Control) or two siRNAs against Fbxl17 (1) and (2) (meanÂ Â±Â SEM from three independent experiments, **<italic>P</italic>Â &lt;Â 0.005, unpaired <italic>t</italic>âtest).</p></list-item><list-item><p>Sufu protein levels in DAOY cells treated as in (A). Representative image of three independent experiments is shown.</p></list-item><list-item><p>Cell proliferation of DAOY cells transfected with nontargeting siRNA (Control), siRNA against Fbxl17 or a combination of siRNA targeting Fbxl17 and Sufu (meanÂ Â±Â SEM from three independent experiments, **<italic>P</italic>Â &lt;Â 0.005; ***<italic>P</italic>Â &lt;<italic>Â </italic>0.0005, unpaired <italic>t</italic>âtest).</p></list-item><list-item><p>Quantification of Fbxl17 mRNA levels in DAOY cells treated as in (D) (meanÂ Â±Â SEM from three independent experiments, ***<italic>P</italic>Â &lt;Â 0.0005, unpaired <italic>t</italic>âtest).</p></list-item><list-item><p>Sufu protein levels in DAOY cells treated as in (D). Representative image of three independent experiments is shown.</p></list-item></list>
</p>
            <p>
<named-content content-type="attribution">Source data are available online for this figure.</named-content>
</p>
          </caption>
          <graphic id="nlm-graphic-21" xlink:href="EMBJ-35-1400-g010"/>
        </fig>
        <p>To investigate the relevance of Fbxl17âSufu axis in cancer, we assessed the effect of RNAi of Fbxl17 <italic>inÂ vivo</italic> by using an orthotopic rat model of medulloblastoma. Fbxl17 RNAi led to an impaired Hh signaling reflected by the accumulation of Sufu protein and decreased Gli1 mRNA (FigÂ <xref rid="embj201593374-fig-0006" ref-type="fig">6</xref>AâC and <xref rid="embj201593374-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S5A</xref>).</p>
        <fig fig-type="Figure" xml:lang="en" id="embj201593374-fig-0006" orientation="portrait" position="float">
          <label>Figure 6</label>
          <caption>
            <title>Fbxl17âmediated degradation of Sufu promotes medulloblastoma tumor growth</title>
            <p>
<list list-type="alpha-upper" id="embj201593374-list-0007"><list-item><p>Quantification of Fbxl17 mRNA levels in DAOY cells transfected with control shRNA or shRNA targeting Fbxl17 (meanÂ Â±Â SEM from three independent experiments, ***<italic>P</italic>Â &lt;<italic>Â </italic>0.0005, unpaired <italic>t</italic>âtest).</p></list-item><list-item><p>Detection of Sufu protein levels in DAOY cells transfected with control shRNA or shRNA Fbxl17. Representative image of three independent experiments is shown.</p></list-item><list-item><p>Quantification of Gli1 mRNA levels in DAOY cells transfected with control shRNA or shRNA Fbxl17 (meanÂ Â±Â SEM from three independent experiments, **<italic>P</italic>Â &lt;Â 0.005, unpaired <italic>t</italic>âtest).</p></list-item><list-item><p>T<sub>2</sub>âweighted magnetic resonance images showing tumor development in rats injected with DAOY cells transfected with control shRNA or shRNA against Fbxl17. One representative image for each condition at 10Â weeks is shown. Scale bar: 5Â mm.</p></list-item><list-item><p>Graph showing area of T<sub>2</sub> hyperintensity (a surrogate marker of tumor growth) between 4 and 10Â weeks postâtumor induction. Animals were injected with DAOY cells stably expressing control shRNA or shRNA against Fbxl17 (10,000Â cells/Î¼l) (meanÂ Â±Â SEM; <italic>n</italic>Â =Â 5; two<bold>â</bold>way ANOVA, followed by unpaired <italic>t</italic>âtest, *<italic>P</italic>Â &lt;Â 0.05, **<italic>P</italic>Â &lt;Â 0.01).</p></list-item><list-item><p>Representative immunohistochemical image of vimentin staining. Scale bar: 1Â mm.</p></list-item><list-item><p>Quantification of tumor growth (vimentin staining) in rats injected with DAOY cells transfected with either control shRNA or shRNA against Fbxl17 (meanÂ Â±Â SEM; <italic>n</italic>Â =Â 5; unpaired <italic>t</italic>âtest, *<italic>P</italic>Â &lt;Â 0.05).</p></list-item><list-item><p>Representative immunohistochemical image of Ki67 staining. Scale bar: 0.5Â mm/0.1Â mm.</p></list-item><list-item><p>Quantification of proliferative index (Ki67 staining) in rats injected with DAOY cells transfected with either control shRNA or shRNA against Fbxl17 (meanÂ Â±Â SEM; <italic>n</italic>Â =Â 5; unpaired <italic>t</italic>âtest, *<italic>P</italic>Â &lt;Â 0.05).</p></list-item></list>
</p>
          </caption>
          <graphic id="nlm-graphic-23" xlink:href="EMBJ-35-1400-g012"/>
        </fig>
        <p>
<italic>In vivo</italic> T<sub>2</sub>âweighted magnetic resonance imaging (MRI) showed a marked reduction in tumor progression over time with RNAi against Fbxl17 (FigÂ <xref rid="embj201593374-fig-0006" ref-type="fig">6</xref>D and E). In contrast, the area of gadolinium enhancement on T<sub>1</sub>âweighted images at the endâpoint showed no differences between groups (<xref rid="embj201593374-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S5B and C</xref>). Histologically, tumors with RNAi against Fbxl17 showed significantly reduced growth compared to a nontargeting control as detected by vimentin staining (6.1Â Â±Â 1.7Â mm<sup>2</sup> vs. 12.4Â Â±Â 1.3Â mm<sup>2</sup>; <italic>P</italic>Â &lt;Â 0.05; FigÂ <xref rid="embj201593374-fig-0006" ref-type="fig">6</xref>F and G), and also a significantly lower proliferative index within the tumor tissue (5.4Â Â±Â 3.6% vs. 20.8Â Â±Â 2.8%; <italic>P</italic>Â &lt;Â 0.05; FigÂ <xref rid="embj201593374-fig-0005" ref-type="fig">5</xref>H and I). Together, these data suggest that T<sub>2</sub>âweighted MRI may be more sensitive to inhibition of tumor growth than postâcontrast T<sub>1</sub>âweighted MRI in this setting.</p>
      </sec>
      <sec id="embj201593374-sec-0008">
        <title>Fbxl17âSufu axis is altered in medulloblastoma</title>
        <p>According to the gene transcription profiles, four different subtypes of medulloblastoma have been described, that is, wingless type (Wnt), Sonic Hedgehog (SHH), group 3, and group 4 (Gajjar &amp; Robinson, <xref rid="embj201593374-bib-0015" ref-type="ref">2014</xref>). The SHH subtype of medulloblastoma is characterized by an increased Hh signaling due to the altered expression of pathway components. Given the relevant role of Fbxl17 in Hh signaling and medulloblastoma growth, we analyzed the mRNA expression of Fbxl17 and Sufu reported in the largest published medulloblastoma expression profiling study (<italic>N</italic>Â =Â 285 primary samples) (Northcott <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0038" ref-type="ref">2012</xref>). Although Sufu has a pivotal role in Hh signaling and mutations in Sufu are present in SHH medulloblastoma, the mRNA of Sufu was found to be not reduced in the SHH subtype, whereas Gli1 was found to be drastically increased (FigÂ <xref rid="embj201593374-fig-0007" ref-type="fig">7</xref>A and B). Strikingly, Fbxl17 mRNA was found to be significantly increased in the SHHâsubtype medulloblastoma (FigÂ <xref rid="embj201593374-fig-0007" ref-type="fig">7</xref>C) and the levels of Fbxl17 and Gli1 positively correlated (Spearman's rhoÂ =Â 0.5640; <italic>P</italic>Â &lt;Â 0.00001; FigÂ <xref rid="embj201593374-fig-0007" ref-type="fig">7</xref>D). In the absence of Sufu mRNA alterations, these results suggest that in medulloblastoma the control of Sufu protein levels by Fbxl17 plays a prominent role in sustaining Hh activation.</p>
        <fig fig-type="Figure" xml:lang="en" id="embj201593374-fig-0007" orientation="portrait" position="float">
          <label>Figure 7</label>
          <caption>
            <title>Fbxl17âSufu axis is altered in medulloblastoma</title>
            <p>
<list list-type="simple" id="embj201593374-list-0008"><list-item><label>AâC</label><p>mRNA expression of Sufu, Gli1, and Fbxl17 detected in 285 medulloblastoma samples (GEO accession: GSE37382), stratified by tumor subtype. Level of significance (<italic>P</italic>) for KruskalâWallis (KW) rank test is <italic>P</italic>Â &lt;Â 10<sup>â8</sup>. Analysis using oneâway ANOVA gave comparable results (medianÂ Â±Â 1.5 interquartile distance).</p></list-item><list-item><label>D</label><p>Expression of Gli1 and Fbxl17 in the 285 patients is shown colored by subgroup; level of significance (<italic>P</italic>) for KruskalâWallis (KW) rank test is <italic>P</italic>Â &lt;Â 10<sup>â8</sup>, and Spearman's rank correlation (<italic>R</italic>Â =Â 0.5640) is indicated.</p></list-item><list-item><label>E</label><p>Detection of HAâtagged Sufu wild type (WT) and HAâtagged Sufu S352F protein levels in NIH3T3 cells after cycloheximide (CHX) treatment. Where indicated, the cells were transfected with a nontargeting siRNA (Control) or two siRNA to Fbxl17 (1) and (2). Representative image of three independent experiments is shown.</p></list-item><list-item><label>F</label><p>Assessment of Hh pathway activation using Gli1âluciferase reporter assay in MEFs <italic>Sufu</italic>
<sup>â/â</sup> upon the reintroduction of HAâtagged Sufu WT or Sufu mutant S352F using a retroviral system (meanÂ Â±Â SEM from three independent experiments, **<italic>P</italic>Â &lt;Â 0.005; ***<italic>P</italic>Â &lt;<italic>Â </italic>0.0005, unpaired <italic>t</italic>âtest).</p></list-item></list>
</p>
          </caption>
          <graphic id="nlm-graphic-25" xlink:href="EMBJ-35-1400-g013"/>
        </fig>
        <p>The distinction of four molecular subgroups depends on the transcriptional profiles of the subgroups, which at least for SHH subtype reflects the cells of origin of the medulloblastoma. In the SHH subtype is established that granule cell progenitors (GCPs) represent the cell of origin of the malignancy (WechslerâReya &amp; Scott, <xref rid="embj201593374-bib-0063" ref-type="ref">1999</xref>; Marino <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0035" ref-type="ref">2000</xref>; Oliver <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0040" ref-type="ref">2005</xref>; Schuller <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0046" ref-type="ref">2008</xref>). Thus, we tested the effect of siRNA and the expression of Fbxl17 in GCPs. Similar to the results obtained in DAOY, Fbxl17 expression increased cell proliferation (FigÂ <xref rid="embj201593374-fig-0005ev" ref-type="fig">EV5</xref>A and B); on the contrary, siRNA of Fbxl17 reduced cell proliferation measured by BrdU incorporation (FigÂ <xref rid="embj201593374-fig-0005ev" ref-type="fig">EV5</xref>C and D).</p>
        <fig fig-type="Figure" xml:lang="en" specific-use="collapsible" id="embj201593374-fig-0005ev" orientation="portrait" position="float">
          <label>Figure EV5</label>
          <caption>
            <title>Fbxl17 regulates the proliferation of granule cell progenitors (<styled-content style="fixed-case">GCP</styled-content>s)</title>
            <p>
<list list-type="alpha-upper" id="embj201593374-list-0014"><list-item><p>Fbxl17 mRNA levels in GCPs after transfection with an empty vector (pCDNA) or a vector expressing MycâFbxl17 (Fbxl17) (meanÂ Â±Â SEM from three independent experiments, **<italic>P</italic>Â &lt;Â 0.005).</p></list-item><list-item><p>Cell proliferation of GCPs upon Fbxl17 overexpression (meanÂ Â±Â SEM from three independent experiments, **<italic>P</italic>Â &lt;Â 0.005).</p></list-item><list-item><p>Fbxl17 mRNA levels in GCPs transfected with either a nontargeting siRNA (Control) or siRNAs to Fbxl17 (meanÂ Â±Â SEM from three independent experiments, **<italic>P</italic>Â &lt;Â 0.005).</p></list-item><list-item><p>Cell proliferation of GCPs upon Fbxl17 depletion (meanÂ Â±Â SEM from four independent experiments, **<italic>P</italic>Â &lt;<italic>Â </italic>0.005).</p></list-item></list>
</p>
            <p>
<named-content content-type="attribution">Source data are available online for this figure.</named-content>
</p>
          </caption>
          <graphic id="nlm-graphic-27" xlink:href="EMBJ-35-1400-g011"/>
        </fig>
        <p>To establish a role for Fbxl17 in the etiology of medulloblastoma through Sufu mutation, we investigated in more detail the Sufu S352F substitution, which favors binding to Fbxl17 (FigÂ <xref rid="embj201593374-fig-0003" ref-type="fig">3</xref>A). This substitution appears in the medulloblastoma of patients affected by Gorlin syndrome and contributes to the medulloblastoma development, in the absence of other alterations in Hh pathway (Smith <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0053" ref-type="ref">2014</xref>). We observed that the halfâlife of Sufu S352F was found to be decreased compared to Sufu WT, in accordance with an increased binding to Fbxl17. Furthermore, silencing of Fbxl17 restored Sufu mutant halfâlife (FigÂ <xref rid="embj201593374-fig-0007" ref-type="fig">7</xref>E). Using firefly luciferaseâbased Gliâreporter assay (Sasaki <italic>et al</italic>, <xref rid="embj201593374-bib-0045" ref-type="ref">1997</xref>), we assessed the effect of Sufu S352F on Hh activation in MEFs <italic>Sufu</italic>
<sup>â/â</sup> reconstituted with either Sufu WT or SufuS352F. Strikingly, Sufu S352F increased the responsiveness of cells to Hh agonist (SAG) (FigÂ <xref rid="embj201593374-fig-0007" ref-type="fig">7</xref>F), indicating that the faster proteolysis of Sufu, mediated by Fbxl17, has a functional role in the control of Hh signaling.</p>
        <p>These observations exemplify the role of Fbxl17âSufu axis alterations in medulloblastoma.</p>
      </sec>
    </sec>
    <sec id="embj201593374-sec-0009">
      <title>Discussion</title>
      <p>Our findings identify Fbxl17 as a novel regulator of Hh signaling pathway. Fbxl17 mediates Sufu polyubiquitylation and degradation through the proteasome. The interaction between Fbxl17 and Sufu is hampered by the phosphorylation of Sufu on S342 andÂ S346 residues, which were shown to be target sites for PKA and GSK3Î², respectively (Chen <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0005" ref-type="ref">2011</xref>) (FigÂ <xref rid="embj201593374-fig-0008" ref-type="fig">8</xref>A). Phosphorylation of Sufu retains it in the primary cilium (Chen <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0005" ref-type="ref">2011</xref>) and could represent a failsafe mechanism to avoid unscheduled pathway activation when the Hh ligands are not present. A similar but opposite mechanism of regulation is operated downstream of Sufu at the levels of Gli2 and Gli3 by the SCF Î²Trcp ubiquitin ligase. In this case, the concerted action of PKA and GSK3Î² generates a phosphorylationâdependent signal for ubiquitylation by Î²Trcp (Bhatia <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0004" ref-type="ref">2006</xref>; Wang &amp; Li, <xref rid="embj201593374-bib-0062" ref-type="ref">2006</xref>). The ubiquitylation of Gli2 and Gli3 generates transcriptional repressors to avoid pathway activation. Thus, PKA and GSK3Î² act on multiple components of Hh pathway as general negative regulators (Chen &amp; Jiang, <xref rid="embj201593374-bib-0006" ref-type="ref">2013</xref>).</p>
      <fig fig-type="Figure" xml:lang="en" id="embj201593374-fig-0008" orientation="portrait" position="float">
        <label>Figure 8</label>
        <caption>
          <title>
<styled-content style="fixed-case">SCF</styled-content> (Fbxl17) ubiquitylation of Sufu regulates Hedgehog signaling and medulloblastoma growth</title>
          <p>
<list list-type="simple" id="embj201593374-list-0009"><list-item><label>AâD</label><p>SchemeÂ outlining the mechanism of Sufu recognition by Fbxl17 and its alteration in medulloblastoma.</p></list-item></list>
</p>
        </caption>
        <graphic id="nlm-graphic-29" xlink:href="EMBJ-35-1400-g014"/>
      </fig>
      <p>Upon Hh ligand binding to Ptch1, a swift activation of the pathway entails the reversal of PKA and GSK3Î² phosphorylation on Sufu S342 and S346, in addition to S352/T353. The dephosphorylation of Sufu initiates Fbxl17 polyubiquitination of Sufu on lysine 257 for proper signal transduction (FigÂ <xref rid="embj201593374-fig-0008" ref-type="fig">8</xref>B). Sufu is upstream of Gli processing (Humke <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0023" ref-type="ref">2010</xref>), and thus, it is tantalizing to speculate that the dephosphorylation of Sufu promotes Gli dephosphorylation for the formation of transcriptional activators. In medulloblastoma, increased expression of Fbxl17 and substitution in critical Sufu residues (S352F), required for Fbxl17 binding, allow amplified pathway activation and increased cell proliferation (FigÂ <xref rid="embj201593374-fig-0008" ref-type="fig">8</xref>C). Inhibition of Fbxl17 blocks Sufu degradation, Hh pathway activation and prevents medulloblastoma tumor growth (FigÂ <xref rid="embj201593374-fig-0008" ref-type="fig">8</xref>D).</p>
      <p>An important feature of Fbxl17âSufu axis is that Fbxl17 acts preferentially on Sufu in complex with Gli1, thus selecting for degradation an active pool of Sufu. Upon Hh signaling activation, Fbxl17âmediated polyubiquitylation of Sufu induces SufuâGli complex dissociation for the transduction of the Hh signal.</p>
      <p>Sufu protein levels are exquisitely sensitive to the degree of Hh activation, indicating that the regulation of Sufu levels by Fbxl17 adds a further layer of control for the generation of more refined transcriptional programs in physiological conditions. Indeed, Fbxl17 could regulate Sufu levels to fineâtune transcriptional outputs; however, more studies are required to establish how the upstream components of the pathway regulate Sufu and Fbxl17. At the same time, it is noteworthy that Fbxl17 transcription is blocked by methylation in embryonic stem cells and transcribed in neural stem cells where Hh plays a more active role (Cortese <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0009" ref-type="ref">2011</xref>). In line with this, Fbxl17 expression is increased in the brain and spinal cord during development (DiezâRoux <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0011" ref-type="ref">2011</xref>), pointing out to a role for Fbxl17 in physiological development. Furthermore, a putative homolog of Fbxl17 (CG31633) has been described in <italic>D.Â melanogaster</italic>, where the absence of the latter induces a pupal lethal phenotype (Dui <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0013" ref-type="ref">2012</xref>), suggesting an essential role of Fbxl17 in development.</p>
      <p>Mutations in the components of Hh signaling are a feature of SHH medulloblastoma (Kool <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0030" ref-type="ref">2014</xref>). We show that in a case of familial medulloblastoma, altered proteolysis of Sufu plays an active role in the induction of sustained Hh signaling. Importantly, mutations in other components of Hh signaling pathway, such as Ptch (present in &gt;Â 50% of SHH medulloblastoma) (Kool <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0030" ref-type="ref">2014</xref>), will also affect Sufu protein levels, given the effect of pathway activation on Sufu protein mediated by Fbxl17. Thus, in the majority of SHH medulloblastoma, Sufu protein levels will be low due to the constitutive activation of Hh signaling. In these cancers, increasing Sufu levels through Fbxl17 inhibition could block Hh signaling and cell proliferation. Overexpression of Fbxl17 in SHH subgroups provides a therapeutic window to selectively target cancer cells. Thus, our study highlights Fbxl17 as a novel target for the treatment of SHH medulloblastoma.</p>
      <p>Other mutations of Sufu residing in critical residues for Fbxl17 binding have been described in colorectal cancer and malignant melanoma (Krauthammer <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0031" ref-type="ref">2012</xref>; Giannakis <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0016" ref-type="ref">2014</xref>); thus, alteration in Fbxl17âSufu axis could be present in other cancer types. The biological significance of these alterations for cell proliferation remains to be determined in these cancers. The use of Smo inhibitors for the treatment of medulloblastoma is being tested in the clinic with encouraging results (Robinson <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0043" ref-type="ref">2015</xref>), but could be significantly prevented by the acquisition of resistance through secondary Smo mutations, described in basal cell carcinoma and medulloblastoma (Yauch <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0066" ref-type="ref">2009</xref>; Atwood <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0002" ref-type="ref">2015</xref>; Sharpe <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0048" ref-type="ref">2015</xref>). In medulloblastoma, the combination of Smo inhibitors and Fbxl17 inhibitors could be a viable alternative strategy to obtain sustained responses.</p>
      <p>Our findings pave the way for the investigation of therapies targeting the ubiquitin proteasome system in the treatment for medulloblastoma and other cancers relying on Hh signaling.</p>
    </sec>
    <sec id="embj201593374-sec-0010">
      <title>Materials and Methods</title>
      <sec id="embj201593374-sec-0011">
        <title>Cell culture</title>
        <p>All cell lines were routinely cultured in a humidified incubator at 37Â°C under 5% CO<sub>2</sub> in the indicated culture medium containing 10% fetal bovine serum (FBS, Sigma Aldrich) supplemented with 100Â U/ml penicillin sodium and 100Â Î¼g/ml streptomycin sulfate (Sigma Aldrich).</p>
        <p>HEK293T, HeLa (ATCC, American Type Culture Collection), and DAOY cells (kind gift from Dr. Maike Glitsch, Department of Physiology, Anatomy and Genetics, University of Oxford, UK) were grown in Dulbecco's modified Eagle's medium (DMEM, Gibco/Invitrogen), while PC3 cells (kindly provided by Dr. Richard Bryant from Ludwig Institute for Cancer Research, University of Oxford, UK) were maintained in RPMI 1640 (Lonza). <italic>Ptch1</italic>
<sup>+/+</sup>, <italic>Ptch1</italic>
<sup>+/â</sup>, and <italic>Ptch1</italic>
<sup>â/â</sup> mouse embryonic fibroblasts (MEFs, kind gift from Dr. Philip Beachy, Department of Biochemistry, Stanford University), <italic>Sufu</italic>
<sup>â/â</sup> MEFs (kindly provided by Dr. Stephan Teglund, Department of Biosciences and Nutrition, Karolinska Institutet, Sweden), and NIH3T3 cells (ATCC) were cultured in DMEM supplemented with 1Â mM sodium pyruvate (Sigma Aldrich) and 0.1Â mM MEM nonessential amino acids (Sigma Aldrich).</p>
      </sec>
      <sec id="embj201593374-sec-0012">
        <title>Hh pathway assays and production of SHHâconditioned medium</title>
        <p>Hyperconfluent DAOY, PC3 cells, and <italic>Sufu</italic>
<sup>â/â</sup> MEFs were starved for 24Â h in serumâreduced medium (DMEM with 0.5% FBS), and subsequently, the Hh signaling pathway was stimulated using Smoothened agonist SAG (100Â nM, Calbiochem) or Sonic Hedgehog (SHH)âconditioned medium (1:4). For Hh signaling inhibition, cyclopamine (Sigma Aldrich) was added to the starvation medium at a final concentration of 10Â Î¼M. DMSO (dimethyl sulfoxide) was used as a solvent and as control vehicle. <italic>Ptch1</italic>
<sup>+/+</sup>, <italic>Ptch1</italic>
<sup>+/â</sup>, and <italic>Ptch1</italic>
<sup>â/â</sup> MEFs were assessed after 24Â h of maintenance in serumâstarved in serumâreduced medium. SHHâconditioned medium was generated as described previously (Cherry <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0007" ref-type="ref">2013</xref>). After 24Â h of incubation with the appropriate Hh pathway agonists, antagonist, or control vehicle, cell cultures were harvested for realâtime PCR or Western blotting.</p>
      </sec>
      <sec id="embj201593374-sec-0013">
        <title>Antibodies</title>
        <p>The following monoclonal antibodies were used: antiâMyc (9B11, mouse, Cell Signaling Technology), antiâHA (05â904, mouse, Millipore and 16B12, Biolegend), antiâSufu (C81H7, rabbit, Cell Signaling Technology), antiâlamin A/C (4C11, Cell Signaling Technology), and antiâvimentin (V9, mouse, Vector Laboratories). Polyclonal antibodies were used as follows: antiâFlag (F7425, rabbit, Sigma Aldrich), antiâFbxl17 (PA5â31396, rabbit, Thermo Fisher Scientific Pierce), antiâGAPDH (MA5â15738, rabbit, Sigma Aldrich), antiâSufu (Câ15, goat, Santa Cruz Biotechnology), antiâKi67 (SP6, rabbit, Vector Laboratories), and antiâSkp1 (kind gift from Dr. Michele Pagano at NYU Cancer Institute, New York University School of Medicine, USA). A rabbit polyclonal antibody against the following peptide of Sufu was raised Hu #347~360: CLESDSâpSâpTâAIIPHEL. To ensure the specific recognition of phosphorylated Sufu, the antibody was affinityâpurified against a phosphorylated peptide and absorbed against a nonphosphorylated peptide CLESDSSTAIIPHEL.</p>
      </sec>
      <sec id="embj201593374-sec-0014">
        <title>Liquid chromatographyâtandem mass spectrometry (LCâMS/MS) analysis</title>
        <p>Flag/Mycâtagged Fbxl17 coâimmunopurified material was eluted by competition using Flag peptide. Supernatant material was subjected to two rounds of chloroformâmethanol precipitation as described (Wessel &amp; Flugge, <xref rid="embj201593374-bib-0064" ref-type="ref">1984</xref>). Samples were then resuspended in 6Â M urea, 100Â mM ammonium acetate pH ~8 and subjected to inâsolution trypsin digestion and analysis by nanoâliquid chromatographyâtandem mass spectrometry as described previously (Ternette <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0060" ref-type="ref">2013</xref>). In brief, after solubilization of the sample pellets, 3Â Î¼l of trypsin (20Â ng/Î¼l, Promega) was added to the samples diluted six times with H<sub>2</sub>O for an overnight digestion at 37Â°C. The samples were then desalted using a C18 SEP PAK cartridge according to the manufacturer's instructions (Waters), dried via Speed Vac centrifugation, and resuspended in 20Â Î¼l of a 2% CH<sub>3</sub>CN/0.1% TFA solution. Peptides were analyzed by nanoâliquid chromatographyâtandem mass spectrometry (nanoâLCâMS/MS) using a NanoâAcquityâUPLC (C18 column with a 75Â Î¼mÂ ÃÂ 250Â mm, 1.7Â Î¼m particle size; Waters) coupled to an Orbitrap Velos tandem mass spectrometer (Thermo Scientific, Bremen, Germany) with a resolution of 70,000 fullâwidth half maximum at mass/charge 400, top 15 precursor ion selection, and fragmentation performed in collisionâinduced dissociation (CID) mode. The samples were loaded in 99.5% buffer A (0.1% FA in H<sub>2</sub>O). The gradient used to elute the peptides started by a 3âmin isocratic gradient composed of 3% buffer B (0.1% FA in CH<sub>3</sub>CN) followed by a linear gradient from 3â40% of buffer B for 60Â min at a flow rate of 250Â nl/min and a two washes with 97% of buffer B for 3Â min. The total length of the analysis was 100Â min to allow the column reâequilibration. The raw MS data were converted into Mascot generic files using MSconvert (Kessner <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0027" ref-type="ref">2008</xref>). Searches were performed using Matrix Science software using the following parameters: The error tolerance was fixed at 20Â ppm for precursor ions and at 0.5Â Da for fragment ions. The enzyme used was trypsin and only one missed cleavage was allowed. MS data were searched against the human uniprotâswissprot database (UniProt_SwissProt, human 20,353 sequences) in which the false discovery rate (FDR) was estimated using a decoy database approach (Mascot) and set toÂ 1%.</p>
      </sec>
      <sec id="embj201593374-sec-0015">
        <title>
<italic>In vivo</italic> and <italic>inÂ vitro</italic> ubiquitylation assay</title>
        <p>HEK293T cells were plated in 10âcm culture dishes at 80% confluence, and 24Â h later, the cells were transfected with the indicated plasmids and incubated for 48Â h. The cells were treated with MG132 (10Â Î¼M) for 5Â h prior to collection. For Fbxl17 silencing, two rounds of siRNA transfections were performed, and the plasmids were delivered to the cells along with the siRNA duplexes in the first round of transfection. Twentyâfour hours after the second round of transfection, the cells were treated with MG132 and collected 5Â h later. The cells were lysed in LB and ubiquitylated Sufu was coâimmunoprecipitated using either antiâHA or antiâSufu antibody coupled to Protein G agarose beads. Polyubiquitinated forms of Sufu were detected by immunoblot using antiâMyc or antiâHA as indicated.</p>
        <p>
<italic>In vitro</italic> ubiquitylation assay was performed using proteins translated in a reticulocyte system, as previously done for SCF Î²Trcp (Dorrello <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0012" ref-type="ref">2006</xref>). Mycâtagged Fbxl17 (318â701) and Sufu WT or Sufu K257R were <italic>inÂ vitro</italic> translated using TnT Quick Coupled Transcription/Translation System reticulocyte system from Promega according to the manufacturer's instructions. After translation, Fbxl17 was mixed with Sufu WT or Sufu K257R in a volume of 40Â Î¼l containing 0.1Â Î¼M E1 (Boston Biochem), 10Â ng/Î¼l Ubch3, 10Â ng/Î¼l Ubch5c, 1Â Î¼M ubiquitin aldehyde, 2.5Â Î¼g/Î¼l ubiquitin (Sigma), in a ubiquitylation buffer (50Â mM Tris pH 7.6, 2Â mM ATP, 5Â mM MgCl<sub>2</sub>, 0.6Â mM DTT, okadaic acid 0.1Â Î¼M). The reaction mixtures were incubated at 30Â°C for the indicated times and analyzed by Western blot of Sufu as indicated.</p>
      </sec>
      <sec id="embj201593374-sec-0016">
        <title>
<italic>In vitro</italic> binding assay</title>
        <p>HAâtagged Sufu fullâlength and MycâtaggedâFbxl17 construct 318â701 was <italic>inÂ vitro</italic>âtranscribed and translated using TNT<sup>Â®</sup> Quick Coupled Transcription/Translation System (Promega) according to the manufacturer's instructions. Proteins were incubated on ice for 1Â h followed by coâimmunoprecipitation of Mycâtagged Fbxl17, using antiâMyc antibody, in binding buffer containing 50Â mM TrisâHCl pH 7.5, 100Â mM NaCl, 2Â mM EDTA, 0.1% NPâ40, and protease inhibitors. Reactions were stopped with Laemmli buffer and resolved by SDSâPAGE.</p>
        <p>Sufu peptides Sufu (340â360), Sufu (340â360) phosphorylated on S352 and T353, and Sufu (351â372) (synthesized by ChinaPeptides Co., Ltd.) were conjugated to CNBrâactivated Sepharose (GE Healthcare) according to the supplier's specifications. HAâtagged Sufu full length synthesized as described above and bound to Protein GâSepharose beads was used as a positive control. Cell lysates of HEK293T cells transfected with Mycâtagged Fbxl17 were used to assess the binding to Sufu peptides using standard coâimmunoprecipitation procedures.</p>
      </sec>
      <sec id="embj201593374-sec-0017">
        <title>
<italic>In vivo</italic> medulloblastoma model</title>
        <p>DAOY cells transfected with either scrambled shRNA or shRNA against Fbxl17 were cultured until approximately 80â90% confluent and then resuspended in PBS for intracerebral injection.</p>
        <p>Two cohorts (<italic>n</italic>Â =Â 5 per group) of male nude rats (Harlan, France), 3â4Â weeks old, were injected intracerebrally in the cerebellar vermis (â11Â mm posterior and 0Â mm lateral to Bregma, and depth 1Â mm) using a finely drawn glass microcapillary (&lt;Â 100Â Î¼m tip). Animals were anaesthetized with 2â3% isoflurane in a mixture of nitrous oxide and oxygen (50%/50%) and placed in a stereotaxic frame (Stoelting Co.). A midline incision was made in the scalp and a burr hole drilled. The animals were injected with 10<sup>4</sup> cells in 1Â Î¼l over a 10âmin period. At the end of the injection, the needle was left in place for 2Â min before being slowly removed. Following injection, the scalp wound was closed and the animals were allowed to recover from anesthesia.</p>
      </sec>
      <sec id="embj201593374-sec-0018">
        <title>Magnetic resonance imaging</title>
        <p>MRI was performed using a horizontal bore 9.4T magnet with a Varian DirectDrive<sup>â¢</sup> (Agilent Technologies, Santa Clara, CA, USA). The animals were anesthetized with 1â2% isoflurane in 70%N<sub>2</sub>/30%O<sub>2</sub> and a cannula positioned in the tail vein for gadoliniumâDTPA (GdâDTPA) injection. The animals were positioned in a quadrature volume transmit coil (i.d. 72Â mm) with four phasedâarray surface receiver coils (i.d.: 40Â mm, RAPID Biomedical GmbH) and placed in the magnet. Body temperature and respiration were monitored throughout and maintained at ~37Â°C and 50 breaths per min, respectively. Multiparametric MRI was acquired including the acquisition of T<sub>1</sub>âweighted images preâ and postâGdâDTPA injection to assess the bloodâbrain barrier (BBB) integrity, and T<sub>2</sub>âweighted images to determine the macroscopic changes in tissue structure, as previously described (Serres <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0047" ref-type="ref">2014</xref>). Briefly, T<sub>2</sub>âweighted images were acquired using a fast spinâecho sequence with a repetition time (TR) of 3.0 s and an effective echo time (TE) of 60Â ms. Spinâecho T<sub>1</sub>âweighted images (TRÂ =Â 500Â ms; TEÂ =Â 20Â ms) were acquired both before and 5Â min after the injection of 100Â Î¼l GdâDTPA (Omniscan<sup>Â®</sup>, GE Healthcare, UK). The matrix size and field of view were 256Â ÃÂ 256 and 3.5Â ÃÂ 3.5Â cm, respectively. In all cases, a multiâslice acquisition was used, spanning the cerebellum with axial slice thickness of 1Â mm.</p>
        <p>Regions of interest (ROI) encompassing areas of visible signal change in the cerebellar vermis were drawn on both the T<sub>2</sub>âweighted and postâGdâDTPA T<sub>1</sub>âweighted images, and the areas were calculated.</p>
      </sec>
      <sec id="embj201593374-sec-0019">
        <title>Statistical analysis</title>
        <p>Quantitative analysis of band intensity was performed using the Image J program. Data are reported as meanÂ Â±Â SEM. Statistical analyses were performed using GraphPad Prism (GraphPad Software, Inc.). Differences between the groups were compared using unpaired Student's <italic>t</italic>âtest.</p>
        <p>Affymetrix Human Gene 1.1 ST Array profiling of 285 primary medulloblastoma samples (Northcott <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0038" ref-type="ref">2012</xref>) was obtained from Gene Expression Omnibus database (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo">http://www.ncbi.nlm.nih.gov/geo</ext-link>), accession: GSE37382. Normalized, logged base 2, gene expression determined using Affymetrix Expression Console (1.1) as previously described (Northcott <italic>etÂ al</italic>, <xref rid="embj201593374-bib-0038" ref-type="ref">2012</xref>) was considered. Oneâway ANOVA and KruskalâWallis tests were both used to test the equality of expression values between the groups. Spearman's rank correlation test was used to test the gene expression association. Data analysis was performed using R.</p>
      </sec>
    </sec>
    <sec id="embj201593374-sec-0021">
      <title>Author contributions</title>
      <p>MR performed most of the biochemical experiments and analyses of cell growth, and EF helped with the biochemical studies. SS, CB, and NRS designed, performed, and analyzed the animal studies. LDM and PI performed the GCPs study. BMK, RF, and MâLT performed the LC/MS analysis of Fbxl17âinteracting proteins. RT and CF provided reagents, protocols, and expert advice for Hh stimulation/experiments. FMB and AB analyzed Fbxl17âSufuâGli1 levels in medulloblastoma. JCC provided expert advice on <italic>inÂ vitro</italic> ubiquitylation experiments. VD'A and MR wrote the manuscript. VD'A coordinated the study and oversaw all experiments. All authors discussed the results, commented on and assisted in revising the manuscript.</p>
    </sec>
    <sec id="embj201593374-sec-0022">
      <title>Conflict of interest</title>
      <p>The authors declare that they have no conflict of interest.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supporting information</title>
      <supplementary-material content-type="local-data"/>
      <supplementary-material content-type="local-data" id="embj201593374-sup-0001">
        <caption>
          <p>Appendix</p>
        </caption>
        <media xlink:href="EMBJ-35-1400-s001.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="embj201593374-sup-0002">
        <caption>
          <p>Expanded View Figures PDF</p>
        </caption>
        <media xlink:href="EMBJ-35-1400-s002.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="embj201593374-sup-0003">
        <caption>
          <p>Source Data for Expanded View</p>
        </caption>
        <media xlink:href="EMBJ-35-1400-s003.zip">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data">
        <caption>
          <p>Review Process File</p>
        </caption>
        <media xlink:href="EMBJ-35-1400-s005.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="embj201593374-supp-data-0001">
        <caption>
          <p>Source Data for FigureÂ 5C</p>
        </caption>
        <media xlink:href="EMBJ-35-1400-s004.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="embj201593374-sec-0020">
      <title>Acknowledgements</title>
      <p>This study was possible thanks to the support of Medical Research Council (MRC) Grant MC_PC_12007 to V.D'A; Cancer Research UK Grant C5255/A12678 to N.R.S.; and grant support to R.T. from the Swedish Research Council, the Swedish Cancer Society, and the Center for Innovative Medicine at Karolinska Institutet. This work was supported by a John Fell (133/075) and Wellcome Trust Grant (097813/Z/11/Z) to B.M.K. and AIRC Grant IG#14723 to L.D.M. We thank Dr. Christian Siebold for the <italic>Sufu</italic> cDNA and advice.</p>
    </ack>
    <ref-list content-type="cited-references" id="embj201593374-bibl-0001">
      <title>References</title>
      <ref id="embj201593374-bib-0002">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0002">
<string-name>
<surname>Atwood</surname>
<given-names>SX</given-names>
</string-name>, <string-name>
<surname>Sarin</surname>
<given-names>KY</given-names>
</string-name>, <string-name>
<surname>Whitson</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Rezaee</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ally</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Oro</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>JY</given-names>
</string-name> (<year>2015</year>) <article-title>Smoothened variants explain the majority of drug resistance in basal cell carcinoma</article-title>. <source>Cancer Cell</source>
<volume>27</volume>: <fpage>342</fpage>â<lpage>353</lpage>
<pub-id pub-id-type="pmid">25759020</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0003">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0003">
<string-name>
<surname>Bassermann</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Eichner</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Pagano</surname>
<given-names>M</given-names>
</string-name> (<year>2014</year>) <article-title>The ubiquitin proteasome system â implications for cell cycle control and the targeted treatment of cancer</article-title>. <source>Biochim Biophys Acta</source>
<volume>1843</volume>: <fpage>150</fpage>â<lpage>162</lpage>
<pub-id pub-id-type="pmid">23466868</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0004">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0004">
<string-name>
<surname>Bhatia</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Thiyagarajan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Elcheva</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Saleem</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dlugosz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Mukhtar</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Spiegelman</surname>
<given-names>VS</given-names>
</string-name> (<year>2006</year>) <article-title>Gli2 is targeted for ubiquitination and degradation by betaâTrCP ubiquitin ligase</article-title>. <source>J Biol Chem</source>
<volume>281</volume>: <fpage>19320</fpage>â<lpage>19326</lpage>
<pub-id pub-id-type="pmid">16651270</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0005">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0005">
<string-name>
<surname>Chen</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yue</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Xie</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Pu</surname>
<given-names>XH</given-names>
</string-name>, <string-name>
<surname>Jin</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>SY</given-names>
</string-name> (<year>2011</year>) <article-title>Dual Phosphorylation of suppressor of fused (Sufu) by PKA and GSK3beta regulates its stability and localization in the primary cilium</article-title>. <source>J Biol Chem</source>
<volume>286</volume>: <fpage>13502</fpage>â<lpage>13511</lpage>
<pub-id pub-id-type="pmid">21317289</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0006">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0006">
<string-name>
<surname>Chen</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>J</given-names>
</string-name> (<year>2013</year>) <article-title>Decoding the phosphorylation code in Hedgehog signal transduction</article-title>. <source>Cell Res</source>
<volume>23</volume>: <fpage>186</fpage>â<lpage>200</lpage>
<pub-id pub-id-type="pmid">23337587</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0007">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0007">
<string-name>
<surname>Cherry</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Finta</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Karlstrom</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jin</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Schwend</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>AstorgaâWells</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zubarev</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Del Campo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Criswell</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>de Sanctis</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Jovine</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Toftgard</surname>
<given-names>R</given-names>
</string-name> (<year>2013</year>) <article-title>Structural basis of SUFUâGLI interaction in human Hedgehog signalling regulation</article-title>. <source>Acta Crystallogr D Biol Crystallogr</source>
<volume>69</volume>: <fpage>2563</fpage>â<lpage>2579</lpage>
<pub-id pub-id-type="pmid">24311597</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0008">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0008">
<string-name>
<surname>Cooper</surname>
<given-names>AF</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>KP</given-names>
</string-name>, <string-name>
<surname>Brueckner</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Brailey</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>McGrath</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Bale</surname>
<given-names>AE</given-names>
</string-name> (<year>2005</year>) <article-title>Cardiac and CNS defects in a mouse with targeted disruption of suppressor of fused</article-title>. <source>Development</source>
<volume>132</volume>: <fpage>4407</fpage>â<lpage>4417</lpage>
<pub-id pub-id-type="pmid">16155214</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0009">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0009">
<string-name>
<surname>Cortese</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lewin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Backdahl</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Krispin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wasserkort</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Eckhardt</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Beck</surname>
<given-names>S</given-names>
</string-name> (<year>2011</year>) <article-title>Genomeâwide screen for differential DNA methylation associated with neural cell differentiation in mouse</article-title>. <source>PLoS ONE</source>
<volume>6</volume>: <fpage>e26002</fpage>
<pub-id pub-id-type="pmid">22028803</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0010">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0010">
<string-name>
<surname>D'Angiolella</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Donato</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Forrester</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Jeong</surname>
<given-names>YT</given-names>
</string-name>, <string-name>
<surname>Pellacani</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kudo</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Saraf</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Florens</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Washburn</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Pagano</surname>
<given-names>M</given-names>
</string-name> (<year>2012</year>) <article-title>Cyclin Fâmediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair</article-title>. <source>Cell</source>
<volume>149</volume>: <fpage>1023</fpage>â<lpage>1034</lpage>
<pub-id pub-id-type="pmid">22632967</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0011">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0011">
<string-name>
<surname>DiezâRoux</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Banfi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sultan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Geffers</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Anand</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Rozado</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Magen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Canidio</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Pagani</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Peluso</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>LinâMarq</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Koch</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bilio</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cantiello</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Verde</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>De Masi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bianchi</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Cicchini</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Perroud</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Mehmeti</surname>
<given-names>S</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2011</year>) <article-title>A highâresolution anatomical atlas of the transcriptome in the mouse embryo</article-title>. <source>PLoS Biol</source>
<volume>9</volume>: <fpage>e1000582</fpage>
<pub-id pub-id-type="pmid">21267068</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0012">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0012">
<string-name>
<surname>Dorrello</surname>
<given-names>NV</given-names>
</string-name>, <string-name>
<surname>Peschiaroli</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Guardavaccaro</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Colburn</surname>
<given-names>NH</given-names>
</string-name>, <string-name>
<surname>Sherman</surname>
<given-names>NE</given-names>
</string-name>, <string-name>
<surname>Pagano</surname>
<given-names>M</given-names>
</string-name> (<year>2006</year>) <article-title>S6K1â and betaTRCPâmediated degradation of PDCD4 promotes protein translation and cell growth</article-title>. <source>Science</source>
<volume>314</volume>: <fpage>467</fpage>â<lpage>471</lpage>
<pub-id pub-id-type="pmid">17053147</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0013">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0013">
<string-name>
<surname>Dui</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Jiao</surname>
<given-names>R</given-names>
</string-name> (<year>2012</year>) <article-title>A systematic phenotypic screen of Fâbox genes through a tissueâspecific RNAiâbased approach in <italic>Drosophila</italic>
</article-title>. <source>J Genet Genomics</source>
<volume>39</volume>: <fpage>397</fpage>â<lpage>413</lpage>
<pub-id pub-id-type="pmid">22884096</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0014">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0014">
<string-name>
<surname>Dunaeva</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Michelson</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kogerman</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Toftgard</surname>
<given-names>R</given-names>
</string-name> (<year>2003</year>) <article-title>Characterization of the physical interaction of Gli proteins with SUFU proteins</article-title>. <source>J Biol Chem</source>
<volume>278</volume>: <fpage>5116</fpage>â<lpage>5122</lpage>
<pub-id pub-id-type="pmid">12426310</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0015">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0015">
<string-name>
<surname>Gajjar</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>
<given-names>GW</given-names>
</string-name> (<year>2014</year>) <article-title>Medulloblastomaâtranslating discoveries from the bench to the bedside</article-title>. <source>Nat Rev Clin Oncol</source>
<volume>11</volume>: <fpage>714</fpage>â<lpage>722</lpage>
<pub-id pub-id-type="pmid">25348790</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0016">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0016">
<string-name>
<surname>Giannakis</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hodis</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Jasmine Mu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Yamauchi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rosenbluh</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Cibulskis</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Saksena</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Lawrence</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Qian</surname>
<given-names>ZR</given-names>
</string-name>, <string-name>
<surname>Nishihara</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Van Allen</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Hahn</surname>
<given-names>WC</given-names>
</string-name>, <string-name>
<surname>Gabriel</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Lander</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Getz</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Ogino</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fuchs</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Garraway</surname>
<given-names>LA</given-names>
</string-name> (<year>2014</year>) <article-title>RNF43 is frequently mutated in colorectal and endometrial cancers</article-title>. <source>Nat Genet</source>
<volume>46</volume>: <fpage>1264</fpage>â<lpage>1266</lpage>
<pub-id pub-id-type="pmid">25344691</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0017">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0017">
<string-name>
<surname>Gotschel</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Berg</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Gruber</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Bender</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Eberl</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Friedel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sonntag</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rungeler</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Hache</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Wierling</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Nietfeld</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Lehrach</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Frischauf</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>SchwartzâAlbiez</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Aberger</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Korf</surname>
<given-names>U</given-names>
</string-name> (<year>2013</year>) <article-title>Synergism between HedgehogâGLI and EGFR signaling in Hedgehogâresponsive human medulloblastoma cells induces downregulation of canonical Hedgehogâtarget genes and stabilized expression of GLI1</article-title>. <source>PLoS ONE</source>
<volume>8</volume>: <fpage>e65403</fpage>
<pub-id pub-id-type="pmid">23762360</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0018">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0018">
<string-name>
<surname>Guardavaccaro</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kudo</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Boulaire</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Barchi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Busino</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Donzelli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>MargottinâGoguet</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Jackson</surname>
<given-names>PK</given-names>
</string-name>, <string-name>
<surname>Yamasaki</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Pagano</surname>
<given-names>M</given-names>
</string-name> (<year>2003</year>) <article-title>Control of meiotic and mitotic progression by the F box protein betaâTrcp1 <italic>inÂ vivo</italic>
</article-title>. <source>Dev Cell</source>
<volume>4</volume>: <fpage>799</fpage>â<lpage>812</lpage>
<pub-id pub-id-type="pmid">12791266</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0019">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0019">
<string-name>
<surname>Hao</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Schulman</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Pagano</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pavletich</surname>
<given-names>NP</given-names>
</string-name> (<year>2005</year>) <article-title>Structural basis of the Cks1âdependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase</article-title>. <source>Mol Cell</source>
<volume>20</volume>: <fpage>9</fpage>â<lpage>19</lpage>
<pub-id pub-id-type="pmid">16209941</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0020">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0020">
<string-name>
<surname>Hooper</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Scott</surname>
<given-names>MP</given-names>
</string-name> (<year>2005</year>) <article-title>Communicating with Hedgehogs</article-title>. <source>Nat Rev Mol Cell Biol</source>
<volume>6</volume>: <fpage>306</fpage>â<lpage>317</lpage>
<pub-id pub-id-type="pmid">15803137</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0021">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0021">
<string-name>
<surname>Hsu</surname>
<given-names>PP</given-names>
</string-name>, <string-name>
<surname>Kang</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Rameseder</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ottina</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Lim</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Peterson</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Gray</surname>
<given-names>NS</given-names>
</string-name>, <string-name>
<surname>Yaffe</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Marto</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Sabatini</surname>
<given-names>DM</given-names>
</string-name> (<year>2011</year>) <article-title>The mTORâregulated phosphoproteome reveals a mechanism of mTORC1âmediated inhibition of growth factor signaling</article-title>. <source>Science</source>
<volume>332</volume>: <fpage>1317</fpage>â<lpage>1322</lpage>
<pub-id pub-id-type="pmid">21659604</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0022">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0022">
<string-name>
<surname>Hui</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Angers</surname>
<given-names>S</given-names>
</string-name> (<year>2011</year>) <article-title>Gli proteins in development and disease</article-title>. <source>Annu Rev Cell Dev Biol</source>
<volume>27</volume>: <fpage>513</fpage>â<lpage>537</lpage>
<pub-id pub-id-type="pmid">21801010</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0023">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0023">
<string-name>
<surname>Humke</surname>
<given-names>EW</given-names>
</string-name>, <string-name>
<surname>Dorn</surname>
<given-names>KV</given-names>
</string-name>, <string-name>
<surname>Milenkovic</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Scott</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Rohatgi</surname>
<given-names>R</given-names>
</string-name> (<year>2010</year>) <article-title>The output of Hedgehog signaling is controlled by the dynamic association between Suppressor of Fused and the Gli proteins</article-title>. <source>Genes Dev</source>
<volume>24</volume>: <fpage>670</fpage>â<lpage>682</lpage>
<pub-id pub-id-type="pmid">20360384</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0024">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0024">
<string-name>
<surname>Ingham</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Nakano</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Seger</surname>
<given-names>C</given-names>
</string-name> (<year>2011</year>) <article-title>Mechanisms and functions of Hedgehog signalling across the metazoa</article-title>. <source>Nat Rev Genet</source>
<volume>12</volume>: <fpage>393</fpage>â<lpage>406</lpage>
<pub-id pub-id-type="pmid">21502959</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0025">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0025">
<string-name>
<surname>Jin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Cardozo</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Lovering</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Elledge</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Pagano</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Harper</surname>
<given-names>JW</given-names>
</string-name> (<year>2004</year>) <article-title>Systematic analysis and nomenclature of mammalian Fâbox proteins</article-title>. <source>Genes Dev</source>
<volume>18</volume>: <fpage>2573</fpage>â<lpage>2580</lpage>
<pub-id pub-id-type="pmid">15520277</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0026">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0026">
<string-name>
<surname>Karhadkar</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Bova</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Abdallah</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Dhara</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gardner</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Maitra</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Isaacs</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Berman</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Beachy</surname>
<given-names>PA</given-names>
</string-name> (<year>2004</year>) <article-title>Hedgehog signalling in prostate regeneration, neoplasia and metastasis</article-title>. <source>Nature</source>
<volume>431</volume>: <fpage>707</fpage>â<lpage>712</lpage>
<pub-id pub-id-type="pmid">15361885</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0027">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0027">
<string-name>
<surname>Kessner</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Chambers</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Burke</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Agus</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Mallick</surname>
<given-names>P</given-names>
</string-name> (<year>2008</year>) <article-title>ProteoWizard: open source software for rapid proteomics tools development</article-title>. <source>Bioinformatics</source>
<volume>24</volume>: <fpage>2534</fpage>â<lpage>2536</lpage>
<pub-id pub-id-type="pmid">18606607</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0028">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0028">
<string-name>
<surname>Kijima</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Miyashita</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Suzuki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Oka</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Fujii</surname>
<given-names>K</given-names>
</string-name> (<year>2012</year>) <article-title>Two cases of nevoid basal cell carcinoma syndrome associated with meningioma caused by a PTCH1 or SUFU germline mutation</article-title>. <source>Fam Cancer</source>
<volume>11</volume>: <fpage>565</fpage>â<lpage>570</lpage>
<pub-id pub-id-type="pmid">22829011</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0029">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0029">
<string-name>
<surname>Kogerman</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Grimm</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kogerman</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Krause</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Unden</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Sandstedt</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Toftgard</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Zaphiropoulos</surname>
<given-names>PG</given-names>
</string-name> (<year>1999</year>) <article-title>Mammalian suppressorâofâfused modulates nuclearâcytoplasmic shuttling of Gliâ1</article-title>. <source>Nat Cell Biol</source>
<volume>1</volume>: <fpage>312</fpage>â<lpage>319</lpage>
<pub-id pub-id-type="pmid">10559945</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0030">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0030">
<string-name>
<surname>Kool</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>DT</given-names>
</string-name>, <string-name>
<surname>Jager</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Northcott</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Pugh</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Hovestadt</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Piro</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Esparza</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Markant</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Remke</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Milde</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Bourdeaut</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Ryzhova</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sturm</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Pfaff</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Stark</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hutter</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>SekerâCin</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Johann</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Bender</surname>
<given-names>S</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2014</year>) <article-title>Genome sequencing of SHH medulloblastoma predicts genotypeârelated response to smoothened inhibition</article-title>. <source>Cancer Cell</source>
<volume>25</volume>: <fpage>393</fpage>â<lpage>405</lpage>
<pub-id pub-id-type="pmid">24651015</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0031">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0031">
<string-name>
<surname>Krauthammer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kong</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ha</surname>
<given-names>BH</given-names>
</string-name>, <string-name>
<surname>Evans</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Bacchiocchi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>McCusker</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Davis</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Goh</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ariyan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Narayan</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>DuttonâRegester</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Capatana</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Holman</surname>
<given-names>EC</given-names>
</string-name>, <string-name>
<surname>Bosenberg</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sznol</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kluger</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Brash</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Stern</surname>
<given-names>DF</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2012</year>) <article-title>Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma</article-title>. <source>Nat Genet</source>
<volume>44</volume>: <fpage>1006</fpage>â<lpage>1014</lpage>
<pub-id pub-id-type="pmid">22842228</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0032">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0032">
<string-name>
<surname>Kuchay</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Duan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Schenkein</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Peschiaroli</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Saraf</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Florens</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Washburn</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Pagano</surname>
<given-names>M</given-names>
</string-name> (<year>2013</year>) <article-title>FBXL2â and PTPL1âmediated degradation of p110âfree p85beta regulatory subunit controls the PI(3)K signalling cascade</article-title>. <source>Nat Cell Biol</source>
<volume>15</volume>: <fpage>472</fpage>â<lpage>480</lpage>
<pub-id pub-id-type="pmid">23604317</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0033">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0033">
<string-name>
<surname>Lee</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kawagoe</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Sasai</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Russell</surname>
<given-names>HR</given-names>
</string-name>, <string-name>
<surname>Curran</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>McKinnon</surname>
<given-names>PJ</given-names>
</string-name> (<year>2007</year>) <article-title>Loss of suppressorâofâfused function promotes tumorigenesis</article-title>. <source>Oncogene</source>
<volume>26</volume>: <fpage>6442</fpage>â<lpage>6447</lpage>
<pub-id pub-id-type="pmid">17452975</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0035">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0035">
<string-name>
<surname>Marino</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Vooijs</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>van Der Gulden</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Jonkers</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Berns</surname>
<given-names>A</given-names>
</string-name> (<year>2000</year>) <article-title>Induction of medulloblastomas in p53ânull mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum</article-title>. <source>Genes Dev</source>
<volume>14</volume>: <fpage>994</fpage>â<lpage>1004</lpage>
<pub-id pub-id-type="pmid">10783170</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0100">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0100">
<string-name>
<surname>Merchant</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vajdos</surname>
<given-names>FF</given-names>
</string-name>, <string-name>
<surname>Ultsch</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Maun</surname>
<given-names>HR</given-names>
</string-name>, <string-name>
<surname>Wendt</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Cannon</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Desmarais</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Lazarus</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>de Vos</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>de Sauvage</surname>
<given-names>FJ</given-names>
</string-name> (<year>2004</year>) <article-title>Suppressor of fused regulates Gli activity through a dual binding mechanism</article-title>. <source>Mol Cell Biol</source>
<volume>24</volume>: <fpage>8627</fpage>â<lpage>8641</lpage>
<pub-id pub-id-type="pmid">15367681</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0038">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0038">
<string-name>
<surname>Northcott</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Shih</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Peacock</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Garzia</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Morrissy</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Zichner</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Stutz</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Korshunov</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Reimand</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Schumacher</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Beroukhim</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ellison</surname>
<given-names>DW</given-names>
</string-name>,Â <string-name>
<surname>Marshall</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Lionel</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Mack</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Dubuc</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ramaswamy</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Luu</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Rolider</surname>
<given-names>A</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2012</year>) <article-title>Subgroupâspecific structural variationÂ across 1,000 medulloblastoma genomes</article-title>. <source>Nature</source>
<volume>488</volume>: <fpage>49</fpage>â<lpage>56</lpage>
<pub-id pub-id-type="pmid">22832581</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0039">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0039">
<string-name>
<surname>Ohh</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>WY</given-names>
</string-name>, <string-name>
<surname>Moslehi</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Chau</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Read</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Kaelin</surname>
<given-names>WG</given-names>
<suffix>Jr</suffix>
</string-name> (<year>2002</year>) <article-title>An intact NEDD8 pathway is required for Cullinâdependent ubiquitylation in mammalian cells</article-title>. <source>EMBO Rep</source>
<volume>3</volume>: <fpage>177</fpage>â<lpage>182</lpage>
<pub-id pub-id-type="pmid">11818338</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0040">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0040">
<string-name>
<surname>Oliver</surname>
<given-names>TG</given-names>
</string-name>, <string-name>
<surname>Read</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Kessler</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Mehmeti</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wells</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Huynh</surname>
<given-names>TT</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>WechslerâReya</surname>
<given-names>RJ</given-names>
</string-name> (<year>2005</year>) <article-title>Loss of patched and disruption of granule cell development in a preâneoplastic stage of medulloblastoma</article-title>. <source>Development</source>
<volume>132</volume>: <fpage>2425</fpage>â<lpage>2439</lpage>
<pub-id pub-id-type="pmid">15843415</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0041">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0041">
<string-name>
<surname>Pastorino</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ghiorzo</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Nasti</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Battistuzzi</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Cusano</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Marzocchi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Garre</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Clementi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Scarra</surname>
<given-names>GB</given-names>
</string-name> (<year>2009</year>) <article-title>Identification of a SUFU germline mutation in a family with Gorlin syndrome</article-title>. <source>Am J Med Genet A</source>
<volume>149A</volume>: <fpage>1539</fpage>â<lpage>1543</lpage>
<pub-id pub-id-type="pmid">19533801</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0042">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0042">
<string-name>
<surname>Peschiaroli</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Dorrello</surname>
<given-names>NV</given-names>
</string-name>, <string-name>
<surname>Guardavaccaro</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Venere</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Halazonetis</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sherman</surname>
<given-names>NE</given-names>
</string-name>, <string-name>
<surname>Pagano</surname>
<given-names>M</given-names>
</string-name> (<year>2006</year>) <article-title>SCFbetaTrCPâmediated degradation of Claspin regulates recovery from the DNA replication checkpoint response</article-title>. <source>Mol Cell</source>
<volume>23</volume>: <fpage>319</fpage>â<lpage>329</lpage>
<pub-id pub-id-type="pmid">16885022</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0043">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0043">
<string-name>
<surname>Robinson</surname>
<given-names>GW</given-names>
</string-name>, <string-name>
<surname>Orr</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Gururangan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Qaddoumi</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Packer</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Goldman</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Prados</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Desjardins</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Chintagumpala</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Takebe</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kaste</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Rusch</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Allen</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>OnarâThomas</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Stewart</surname>
<given-names>CF</given-names>
</string-name>, <string-name>
<surname>Fouladi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Boyett</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Gilbertson</surname>
<given-names>RJ</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2015</year>) <article-title>Vismodegib exerts targeted efficacy against recurrent sonic hedgehogâsubgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies PBTCâ025B and PBTCâ032</article-title>. <source>J Clin Oncol</source>
<volume>33</volume>: <fpage>2646</fpage>â<lpage>2654</lpage>
<pub-id pub-id-type="pmid">26169613</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0044">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0044">
<string-name>
<surname>Sanchez</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hernandez</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Stecca</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Kahler</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>DeGueme</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Barrett</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Beyna</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Datta</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Datta</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ruiz i Altaba</surname>
<given-names>A</given-names>
</string-name> (<year>2004</year>) <article-title>Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOGâGLI1 signaling</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>101</volume>: <fpage>12561</fpage>â<lpage>12566</lpage>
<pub-id pub-id-type="pmid">15314219</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0045">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0045">
<string-name>
<surname>Sasaki</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hui</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Nakafuku</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kondoh</surname>
<given-names>H</given-names>
</string-name> (<year>1997</year>) <article-title>A binding site for Gli proteins is essential for HNFâ3beta floor plate enhancer activity in transgenics and can respond to Shh <italic>inÂ vitro</italic>
</article-title>. <source>Development</source>
<volume>124</volume>: <fpage>1313</fpage>â<lpage>1322</lpage>
<pub-id pub-id-type="pmid">9118802</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0046">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0046">
<string-name>
<surname>Schuller</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Heine</surname>
<given-names>VM</given-names>
</string-name>, <string-name>
<surname>Mao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kho</surname>
<given-names>AT</given-names>
</string-name>, <string-name>
<surname>Dillon</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>YG</given-names>
</string-name>, <string-name>
<surname>Huillard</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ligon</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Qian</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>AlvarezâBuylla</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>McMahon</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Rowitch</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Ligon</surname>
<given-names>KL</given-names>
</string-name> (<year>2008</year>) <article-title>Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence toÂ formÂ Shhâinduced medulloblastoma</article-title>. <source>Cancer Cell</source>
<volume>14</volume>: <fpage>123</fpage>â<lpage>134</lpage>
<pub-id pub-id-type="pmid">18691547</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0047">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0047">
<string-name>
<surname>Serres</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Martin</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Sarmiento Soto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bristow</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>O'Brien</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Connell</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Khrapitchev</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Sibson</surname>
<given-names>NR</given-names>
</string-name> (<year>2014</year>) <article-title>Structural and functional effects of metastases in rat brain determined by multimodal MRI</article-title>. <source>Int J Cancer</source>
<volume>134</volume>: <fpage>885</fpage>â<lpage>896</lpage>
<pub-id pub-id-type="pmid">23913394</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0048">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0048">
<string-name>
<surname>Sharpe</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Pau</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Dijkgraaf</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>BassetâSeguin</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Modrusan</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Januario</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tsui</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Durham</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Dlugosz</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Haverty</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Bourgon</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Sarin</surname>
<given-names>KY</given-names>
</string-name>, <string-name>
<surname>Dirix</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Fisher</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Rudin</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Sofen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Migden</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Yauch</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>de Sauvage</surname>
<given-names>FJ</given-names>
</string-name> (<year>2015</year>) <article-title>Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma</article-title>. <source>Cancer Cell</source>
<volume>27</volume>: <fpage>327</fpage>â<lpage>341</lpage>
<pub-id pub-id-type="pmid">25759019</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0049">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0049">
<string-name>
<surname>Sheng</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Chi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>McCormick</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Gatalica</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Xie</surname>
<given-names>J</given-names>
</string-name> (<year>2004</year>) <article-title>Activation of the hedgehog pathway in advanced prostate cancer</article-title>. <source>Mol Cancer</source>
<volume>3</volume>: <fpage>29</fpage>
<pub-id pub-id-type="pmid">15482598</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0050">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0050">
<string-name>
<surname>Skaar</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>D'Angiolella</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Pagan</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Pagano</surname>
<given-names>M</given-names>
</string-name> (<year>2009</year>) <article-title>SnapShot: F BoxÂ Proteins II</article-title>. <source>Cell</source>
<volume>137</volume>: <fpage>1358</fpage>, 1358.e1351<pub-id pub-id-type="pmid">19563764</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0051">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0051">
<string-name>
<surname>Skaar</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Pagan</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Pagano</surname>
<given-names>M</given-names>
</string-name> (<year>2013</year>) <article-title>Mechanisms and function of substrate recruitment by Fâbox proteins</article-title>. <source>Nat Rev Mol Cell Biol</source>
<volume>14</volume>: <fpage>369</fpage>â<lpage>381</lpage>
<pub-id pub-id-type="pmid">23657496</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0052">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0052">
<string-name>
<surname>Skaar</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Pagan</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Pagano</surname>
<given-names>M</given-names>
</string-name> (<year>2014</year>) <article-title>SCF ubiquitin ligaseâtargeted therapies</article-title>. <source>Nat Rev Drug Discovery</source>
<volume>13</volume>: <fpage>889</fpage>â<lpage>903</lpage>
<pub-id pub-id-type="pmid">25394868</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0053">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0053">
<string-name>
<surname>Smith</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Beetz</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Bhaskar</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>O'Sullivan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Daly</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Urquhart</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Bholah</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Oudit</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Cheesman</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kelsey</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>McCabe</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Newman</surname>
<given-names>WG</given-names>
</string-name>, <string-name>
<surname>Evans</surname>
<given-names>DG</given-names>
</string-name> (<year>2014</year>) <article-title>Germline mutations in SUFU cause Gorlin syndromeâassociated childhood medulloblastoma and redefineÂ the risk associated with PTCH1 mutations</article-title>. <source>J Clin Oncol</source>
<volume>32</volume>: <fpage>4155</fpage>â<lpage>4161</lpage>
<pub-id pub-id-type="pmid">25403219</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0054">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0054">
<string-name>
<surname>Soucy</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Milhollen</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Berger</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Gavin</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Adhikari</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Brownell</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Burke</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Cardin</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Critchley</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Cullis</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Doucette</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Garnsey</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Gaulin</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Gershman</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Lublinsky</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>McDonald</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Mizutani</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Narayanan</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Olhava</surname>
<given-names>EJ</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2009</year>) <article-title>An inhibitor of NEDD8âactivating enzyme as a new approach to treat cancer</article-title>. <source>Nature</source>
<volume>458</volume>: <fpage>732</fpage>â<lpage>736</lpage>
<pub-id pub-id-type="pmid">19360080</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0055">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0055">
<string-name>
<surname>Svard</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>HebyâHenricson</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>PerssonâLek</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rozell</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Lauth</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bergstrom</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ericson</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Toftgard</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Teglund</surname>
<given-names>S</given-names>
</string-name> (<year>2006</year>) <article-title>Genetic elimination of Suppressor of fused reveals an essential repressor function in the mammalian Hedgehog signaling pathway</article-title>. <source>Dev Cell</source>
<volume>10</volume>: <fpage>187</fpage>â<lpage>197</lpage>
<pub-id pub-id-type="pmid">16459298</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0056">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0056">
<string-name>
<surname>Taipale</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Cooper</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Mann</surname>
<given-names>RK</given-names>
</string-name>, <string-name>
<surname>Milenkovic</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Scott</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Beachy</surname>
<given-names>PA</given-names>
</string-name> (<year>2000</year>) <article-title>Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine</article-title>. <source>Nature</source>
<volume>406</volume>: <fpage>1005</fpage>â<lpage>1009</lpage>
<pub-id pub-id-type="pmid">10984056</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0057">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0057">
<string-name>
<surname>Tan</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Lim</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Harper</surname>
<given-names>JW</given-names>
</string-name> (<year>2013</year>) <article-title>Parallel SCF adaptor capture proteomics reveals a role for SCFFBXL17 in NRF2 activation via BACH1 repressor turnover</article-title>. <source>Mol Cell</source>
<volume>52</volume>: <fpage>9</fpage>â<lpage>24</lpage>
<pub-id pub-id-type="pmid">24035498</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0058">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0058">
<string-name>
<surname>Taylor</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Raffel</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hui</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Mainprize</surname>
<given-names>TG</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Agatep</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Chiappa</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Lowrance</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hao</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Goldstein</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Stavrou</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Scherer</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Dura</surname>
<given-names>WT</given-names>
</string-name>, <string-name>
<surname>Wainwright</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Squire</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Rutka</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Hogg</surname>
<given-names>D</given-names>
</string-name> (<year>2002</year>) <article-title>Mutations in SUFU predispose to medulloblastoma</article-title>. <source>Nat Genet</source>
<volume>31</volume>: <fpage>306</fpage>â<lpage>310</lpage>
<pub-id pub-id-type="pmid">12068298</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0059">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0059">
<string-name>
<surname>Teglund</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Toftgard</surname>
<given-names>R</given-names>
</string-name> (<year>2010</year>) <article-title>Hedgehog beyond medulloblastoma and basal cell carcinoma</article-title>. <source>Biochim Biophys Acta</source>
<volume>1805</volume>: <fpage>181</fpage>â<lpage>208</lpage>
<pub-id pub-id-type="pmid">20085802</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0060">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0060">
<string-name>
<surname>Ternette</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Laroyia</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kitagawa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>O'Flaherty</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wolhulter</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Igarashi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Saito</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kato</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Fischer</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Berquand</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kessler</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Lappin</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Frizzell</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Soga</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Adam</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Pollard</surname>
<given-names>PJ</given-names>
</string-name> (<year>2013</year>) <article-title>Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency</article-title>. <source>Cell Rep</source>
<volume>3</volume>: <fpage>689</fpage>â<lpage>700</lpage>
<pub-id pub-id-type="pmid">23499446</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0061">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0061">
<string-name>
<surname>Tukachinsky</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Lopez</surname>
<given-names>LV</given-names>
</string-name>, <string-name>
<surname>Salic</surname>
<given-names>A</given-names>
</string-name> (<year>2010</year>) <article-title>A mechanism for vertebrate Hedgehog signaling: recruitment to cilia and dissociation of SuFuâGli protein complexes</article-title>. <source>J Cell Biol</source>
<volume>191</volume>: <fpage>415</fpage>â<lpage>428</lpage>
<pub-id pub-id-type="pmid">20956384</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0062">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0062">
<string-name>
<surname>Wang</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name> (<year>2006</year>) <article-title>Evidence for the direct involvement of {beta}TrCP in Gli3 protein processing</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>103</volume>: <fpage>33</fpage>â<lpage>38</lpage>
<pub-id pub-id-type="pmid">16371461</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0063">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0063">
<string-name>
<surname>WechslerâReya</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Scott</surname>
<given-names>MP</given-names>
</string-name> (<year>1999</year>) <article-title>Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog</article-title>. <source>Neuron</source>
<volume>22</volume>: <fpage>103</fpage>â<lpage>114</lpage>
<pub-id pub-id-type="pmid">10027293</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0064">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0064">
<string-name>
<surname>Wessel</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Flugge</surname>
<given-names>UI</given-names>
</string-name> (<year>1984</year>) <article-title>A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids</article-title>. <source>Anal Biochem</source>
<volume>138</volume>: <fpage>141</fpage>â<lpage>143</lpage>
<pub-id pub-id-type="pmid">6731838</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0065">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0065">
<string-name>
<surname>Xing</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Busino</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hinds</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Marionni</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Saifee</surname>
<given-names>NH</given-names>
</string-name>, <string-name>
<surname>Bush</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Pagano</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>N</given-names>
</string-name> (<year>2013</year>) <article-title>SCF(FBXL3) ubiquitin ligase targets cryptochromes at their cofactor pocket</article-title>. <source>Nature</source>
<volume>496</volume>: <fpage>64</fpage>â<lpage>68</lpage>
<pub-id pub-id-type="pmid">23503662</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0066">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0066">
<string-name>
<surname>Yauch</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Dijkgraaf</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Alicke</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Januario</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ahn</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Holcomb</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Pujara</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Stinson</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Callahan</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Bazan</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Kan</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Seshagiri</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hann</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Gould</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Low</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Rudin</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>de Sauvage</surname>
<given-names>FJ</given-names>
</string-name> (<year>2009</year>) <article-title>Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma</article-title>. <source>Science</source>
<volume>326</volume>: <fpage>572</fpage>â<lpage>574</lpage>
<pub-id pub-id-type="pmid">19726788</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0067">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0067">
<string-name>
<surname>Yue</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>SY</given-names>
</string-name> (<year>2009</year>) <article-title>Hedgehog signaling promotes the degradation of tumor suppressor Sufu through the ubiquitinâproteasome pathway</article-title>. <source>Oncogene</source>
<volume>28</volume>: <fpage>492</fpage>â<lpage>499</lpage>
<pub-id pub-id-type="pmid">18997815</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0068">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0068">
<string-name>
<surname>Zhang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lipinski</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Shaw</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gipp</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bushman</surname>
<given-names>W</given-names>
</string-name> (<year>2007</year>) <article-title>Lack of demonstrable autocrine hedgehog signaling in human prostate cancer cell lines</article-title>. <source>J Urol</source>
<volume>177</volume>: <fpage>1179</fpage>â<lpage>1185</lpage>
<pub-id pub-id-type="pmid">17296441</pub-id></mixed-citation>
      </ref>
      <ref id="embj201593374-bib-0069">
        <mixed-citation publication-type="journal" id="embj201593374-cit-0069">
<string-name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Fu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Qi</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Xia</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Jia</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>G</given-names>
</string-name> (<year>2013</year>) <article-title>Structural insight into the mutual recognition and regulation betweenÂ Suppressor of Fused and Gli/Ci</article-title>. <source>Nat Commun</source>
<volume>4</volume>: <fpage>2608</fpage>
<pub-id pub-id-type="pmid">24217340</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>